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Abstract 
 Upper airway collapse in obstructive sleep apnea (OSA) is associated with intermittent 
hypoxia, which resembles ischemia-reperfusion (IR). Oxidative stress in IR has been shown to 
increase matrix metalloproteinases (MMPs) action and lead to adverse cardiovascular 
consequences in animal models. The results of previous studies on circulating MMP level in 
OSA are inconsistent. Oxidative stress in OSA might also directly contribute to kidney injury. 
The alteration in urinary MMP levels have been previously shown in acute and chronic renal 
injury, but there is no data about MMP levels in urine of OSA patients.  
The aim of this study is to determine if serum and urine MMPs in OSA patients are 
associated with OSA severity and CVD in OSA. 
The study is a part of a multi-center Canadian trial performed through the Canadian 
Sleep and Circadian Network. OSA subjects (n=124) were recruited from the Sleep Disorders 
Center (Saskatoon City Hospital, Saskatchewan, Canada) after in-lab polysomnography (PSG). 
Controls (n=26) were subjects referred to the Center who did not have OSA. Severity of OSA 
was categorized based on apnea/hypopnea index (AHI) according to American Academy of 
Sleep Medicine criteria. Level of hypoxemia was expressed as oxygen desaturation index 
(ODI). MMP-2 and MMP-9 activities were measured in blood and urine samples with gelatin 
zymography method. Albumin-to-creatinine ratio (ACR - indicator of glomerular damage) was 
calculated from urinary albumin and creatinine. Mann-Whitney U and Kruskal-Wallis tests 
were used for statistical analysis. Multivariable linear regression was used to control for 
potential confounders. 
Serum MMP-2 activity was associated with OSA severity/level of hypoxemia in OSA, 
even after adjustment for age, sex, body mass index (BMI), and CVD (p = 0.004). In stratified 
analysis, the association between serum MMP-2 and AHI remained significant only for patients 
with CVD (p = 0.009). Serum MMP-9 was associated with white blood cell count, after 
adjustment for AHI, age, sex, BMI and CVD (p < 0.001). Urinary MMPs did not show any 
association with OSA severity. Urinary MMP-2-to-creatinine in OSA was associated with 
ACR, independently of hypertension and diabetes (p = 0.022). There were no differences in 
MMP activities between OSA patients with CVD and without CVD. 
The results suggest that in future studies serum MMP-2 might be considered as 
biomarker of OSA severity, whereas MMP-9 may be a marker of inflammation in OSA. 
Urinary MMP-2 was associated with glomerular damage in OSA. Prospective studies in larger 
sample size are needed to confirm and delineate observed associations. 
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 INTRODUCTION 
Obstructive sleep apnea (OSA) is the most common sleep-related breathing disorder, 
characterized by recurrent episodes of upper airway obstruction leading to intermittent hypoxia 
and arousals [1]. Nearly 1 billion individuals aged 30–69 years worldwide are estimated to 
have OSA, with prevalence exceeding 50% in some countries [2]. The prevalence of OSA has 
been increasing [3]. In the biennial Canadian Health Measures Survey (2016-2017) 6.4% of 
adult Canadians reported they had been diagnosed with sleep apnea [4], whereas the prevalence 
among adults reported in the Canadian Community Health Survey in 2009 was 3% [5]. 
Due to poor sleep quality, patients with OSA frequently experience daytime 
somnolence and fatigue, which is associated with worse work performance and higher risk of 
motor vehicle crashes [1,6]. Moreover, severity of OSA is associated with an increased risk of 
cardiovascular disease (CVD) [7]. Current evidence suggests that it is predominantly the 
hypoxic burden that contributes to the emergence of CV complications of OSA which affect 
primarily those with severe disease. The main challenge of clinical management of OSA is to 
identify which patients are at higher risk of these adverse consequences. Finding a simple non-
invasive biomarker for assessing OSA severity and hypoxic burden would allow to stratify risk 
and to implement proper therapy early in the course of disease to prevent development and/or 
progression of the adverse cardiovascular complications [8]. 
The pathophysiology of OSA comorbidities is likely multifactorial. Chronic 
intermittent hypoxia (CIH) in OSA results in inflammation, endothelial dysfunction, elevated 
oxidative stress, and sympathetic nervous system activation [9]. Considering the complexity of 
OSA, many biomarkers, including markers of inflammation, oxidative stress, catecholamines 
and adhesion molecules, have been already proposed, however, the results are still inconclusive 
[8]. 
Recurrent episodes of apneas/hypopneas in OSA cause a desaturation-reoxygenation 
sequence. It resembles ischemia/reperfusion injury (IRI) which is associated with excessive 
production of reactive oxygen species (ROS)/reactive nitrogen species (RNS) [10]. ROS/RNS 
are highly reactive molecules that, if at high quantities, can cause damage to the nucleic acids, 
lipids and proteins, and in turn contribute to numerous pathological conditions, including CVD. 
The imbalance between ROS and antioxidant defence is called an oxidative stress [11]. 
Oxidative stress during ischemia/reperfusion or asphyxia causes an increase in matrix 
metalloproteinases (MMPs) action and leads to adverse cardiovascular consequences [12–14]. 
An upregulation of oxidative stress markers and impaired antioxidant capacity in OSA has been 
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previously shown [10]. MMPs action can therefore be a molecular mechanism linking OSA 
with oxidative stress and CVD. 
There is some evidence of associations between MMPs and OSA severity, which was 
described in a recent systematic review (see Chapter 2) [15]. However, the published studies 
are limited by their experimental design, small subject numbers, and/or lack of adjustment for 
potential confounders. The vast majority of published results in humans investigated MMP-9 
levels. However in animal models there is strong evidence of role of MMP-2 in oxidative stress 
[16–18]. 
Although OSA is associated with a loss of kidney function [19] and microalbuminuria 
[20], so far there is no data on MMPs in the urine of OSA patients. Increased risk of loss of 
kidney function in OSA can be related to OSA co-morbidities (such as hypertension, diabetes), 
but oxidative stress often seen in OSA patients might directly contribute to kidney injury. Thus, 
some biochemical changes (including protein release and modification in protein profile) in 
urine of OSA patients may be observed. 
 
1.1 Obstructive sleep apnea 
1.1.1 Pathogenesis and pathophysiologic consequences 
OSA is a disorder characterized by episodes of markedly reduced (hypopnea) or absent 
(apnea) airflow during sleep, caused by the decrease of upper airway dilating muscle activity 
superimposed on a narrow upper airway [1]. These episodes are usually accompanied by blood 
oxygen desaturation, fluctuations in blood pressure and heart rate, and are typically terminated 
by micro-arousals [21,22]. 
OSA risk factors include male sex, age 40-70 years, obesity, large neck, craniofacial 
abnormalities, smoking, use of sedatives before sleep, and select endocrinological disorders 
associated with abnormal upper airway anatomy or physiology (hypothyroidism, acromegaly) 
[6].  Several published studies have established the role of genetic factors in the development 
of OSA [23]. The pathophysiological factors for OSA that appear to be influenced by genetic 
factors include differences in body fat distribution, control of breathing, and craniofacial and 
upper airway morphology [22,23].  
OSA significantly impacts quality of life. Among major sequelae are habitual snoring, 
excessive daytime sleepiness due to poor sleep quality, daytime fatigue, poor work 
performance, and higher risk of motor vehicle crashes [6]. Furthermore, OSA has numerous 
other serious health consequences. Patients with OSA are at higher risk of developing 
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cardiometabolic diseases, including systemic and pulmonary hypertension, heart failure, 
atherosclerosis, coronary artery disease, stroke, diabetes and metabolic syndrome [24].  
Moreover, intermittent hypoxia, activation of sympathetic nervous system and OSA 
comorbidities (hypertension, diabetes) may lead to development of chronic kidney disease 
and/or its progression in OSA [25]. OSA has been previously shown to be associated with 
kidney injury [20] and accelerated loss of kidney function [19]. 
 
1.1.2 Diagnosis and classification of severity. 
 The gold standard for OSA diagnosis is in-lab polysomnography (PSG). It is a 
comprehensive overnight study during which neurologic and cardio-respiratory parameters are 
recorded, including air flow, respiratory effort, blood oxygen saturation, electrocardiogram 
(EKG), electrical activity of the brain (EEG), eyes (EOG), muscle tone (EMG) and body 
movements [6]. 
 According to current American Academy of Sleep Medicine (AASM) criteria [26], 
severity of OSA is categorized based on apnea/hypopnea index (AHI) which is the number of 
apneas and hypopneas per hour. Apnea is defined as a cessation of breathing for a minimum of 
10 seconds. Hypopnea is defined as a decrease of airflow for more than 10 seconds associated 
with oxygen desaturation of 3% or an arousal. Severity of OSA is defined as follows: ≥ 5/h 
(mild OSA), ≥ 15/h (moderate OSA), ≥ 30/h (severe OSA) [26]. 
 
1.1.3 Treatment 
OSA treatment depends on the severity of disease. Patients with OSA can largely 
benefit from reduction in risk factors, namely weight loss, avoidance sedatives before sleep, or 
sleeping on the side. The therapy of choice for patients with moderate-to-severe sleep apnea is 
continuous positive airway pressure (CPAP) therapy. CPAP is a device that provides a positive 
airway pressure to upper airway during sleep to ensure the airway stays open. CPAP therapy 
reduces daytime sleepiness and other symptoms, and improves sleep and quality of life [27]. 
Moreover, it has been shown that CPAP  reduces the risk of fatal and non-fatal cardiovascular 
events in OSA patients [28].  
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1.2  Matrix metalloproteinases 
MMPs are a family of over 20 calcium–activated and zinc-dependent endopeptidases 
[29]. They are responsible for degradation of extracellular matrix (ECM), but it has been shown 
that MMPs act also at the intracellular level [30]. 
MMPs were discovered in 1962, when Gross and Lapiere tried to establish how the 
metamorphosing frog tadpole lost its tail. They found a collagenolytic activity in amphibian 
tissue, and it was later named matrix metalloproteinase-1. MMPs are found in most living 
organisms [31]. 
Based on substrate specificity and structural homology MMPs are classified into the 
following groups: collagenases, gelatinases, stromelysins, matrilysins, membrane-type (MT)-
MMPs and other non-classified MMPs [32]. 
 
1.2.1 Gelatinases (MMP-2 and MMP-9) 
1.2.1.1 Substrate specificity and function 
Gelatinases are the most studied MMPs. MMP-2 is a constitutive enzyme found in 
almost all cell types, including endothelium, vascular smooth muscle cells, cardiomyocytes 
and connective tissue cells [16,33]. MMP-9 is expressed in endothelium, cardiomyocytes, 
smooth muscle cells, but mainly in leukocytes, and it is easily induced by pro-inflammatory 
cytokines [16,34]. 
Gelatinases are known to cleave native collagen type IV, V, VII and X, XI, as well as 
elastin and fibronectin [29]. The first evidence of intracellular localization and action of MMP-
2 was shown in 1997 [35]. The group discovered an MMP-2-mediated pathway of human 
platelet aggregation, and described the ultrastructural localization and cellular translocation of 
MMP-2 in the stimulated human platelets [35]. Following this study, several new intracellular 
actions of MMPs were revealed, including degradation of big endothelin [36], monocyte 
chemoattractant protein-3 [37] and cardiac contractile proteins including troponin I [38], titin 
[39] and myosin light chain type 1 and 2 [14,40]. 
Gelatinases play an important role in a variety of physiological processes including 
morphogenesis, cartilage and bone repair, wound healing, cell migration and angiogenesis [16]. 
The dysregulation of MMPs’ action leads to development of many pathological conditions, 
such as chronic ulcers, rheumatoid arthritis, cancers and CVD [41]. They have been shown to 
play a role in development of dilated cardiomyopathy, cardiac remodeling after myocardial 
infarction and atherosclerotic plaque rupture [42]. MMPs, apart from the involvement in 
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chronic (days-weeks) processes [43], have also been found to increase their activity within 
minutes, for example in acute IRI in the heart [44]. 
 
1.2.1.2 Structure 
MMP-2 and MMP-9 structure includes a signal peptide, amino-terminal propeptide, a 
zinc-binding domain containing the catalytic site, and a carboxyl-terminal hemopexin-like 
domain [32]. Additionally, MMP-2 and MMP-9 have fibronectin-like gelatin-binding domain 
which contributes to their substrate specificity [34]. MMP-2 and MMP-9 were assigned to 
MMP family due to their sequence homology with MMP-1: a highly conserved sequence 
PRCGXPD in the propeptide, and the sequence HEXGHXXGXXH in the catalytic domain 
[30]. 
The signal peptide is responsible for guiding the transport of enzymes into the 
endoplasmic reticulum. The propeptide domain maintains the proenzyme in an inactive state 
(by interaction between the cysteine residue in a propeptide with the active zinc ion site in the 
catalytic domain). Catalytic domain, apart from one catalytic zinc, contains one structural zinc, 
and three calcium ions. The catalytic zinc ion is stabilized within the catalytic domain by three 
histidine residues (located in the highly conserved sequence HEXGHXXGXXH). [30,34]. 
The hemopexin-like domain facilitates the interaction between MMPs and tissue 
inhibitor of metalloproteinases (TIMPs), and it is not required for catalytic activity [30,34]. 
 
1.2.1.3 Regulation of activity 
MMPs are expressed as latent enzymes. They are activated by the disruption of bond 
between a cysteine thiol residue and the active zinc ion site. This can be achieved by two 
mechanisms. First, several proteases (such as plasminogen, kallikrein, tissue plasminogen 
activator, trypsin as well as MMPs themselves) can cause proteolysis of the propeptide domain. 
Secondly, ROS can directly change a protein conformation exposing catalytic site of MMP 
[45]. 
During activation by proteolytic cleavage of proenzyme, the active form is then shorter 
by approximately 10 kDa compared to proenzyme. In case of activation by oxidants without 
proteolytic cleavage, activated form is same size as the latent form. 
MMP activity may be regulated at multiple levels including transcription, secretion, 
activation or suppression by specific and nonspecific inhibitors [45].  
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Due to the fact that MMP-2 is constitutively expressed by many cells, its activity 
depends more on post-translational events than transcriptional regulation. Unlike MMP-2, 
MMP-9 gene is highly inducible by pro-inflammatory cytokines and oncogene products, which 
may increase its transcription by as much as 100-fold [34]. 
MMPs are naturally inhibited by α2-macroglobulin and the endogenous tissue 
inhibitors of metalloproteinases (TIMPs). Human α2-macroglobulin is a plasma glycoprotein 
with the function of binding of MMPs, and then their removal from the circulation via 
scavenger receptors on the phagocytes [30,46]. 
 TIMPs are a family of small proteins (20-30 kDa), which inhibit MMPs by forming 
non-covalent complex in a 1:1 molecular ratio. To date, four TIMP isoforms have been 
identified (TIMP-1, TIMP-2, TIMP-3, TIMP-4). They are broad-spectrum inhibitors of MMPs, 
but they show some differences in specificity, for example TIMP-1 strongly binds to MMP-9, 
whereas TIMP-2 preferentially modulates activity of MMP-2 [34,47].  
Synthetic inhibitors of MMPs, such as o-phenanthroline, hydroxamates and 
tetracyclines, inhibits MMPs by chelating zinc ion in their catalytic site. Currently, doxycycline 
is the only clinically approved inhibitor of MMPs [45].  
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 OBJECTIVES AND HYPOTHESIS 
My overall aim of this project was to investigate the relationship between OSA and 
MMPs. Based on the literature presented, it was hypothesized that urinary and serum MMPs 
may be biomarkers of hypoxemia severity and the severity of OSA. This study was a step 
towards identification of a biomarker for risk stratification, triage of OSA patients, and a 
marker which can provide the opportunity for more targeted therapy for OSA. 
 
Objective 1: To determine if adult OSA (obstructive sleep apnea) patients have a distinct serum 
and urine MMPs (matrix metalloproteinases) levels when compared to controls. 
Hypothesis 1: Serum and urine levels of MMP-2 and MMP-9 are increased in OSA patients 
 
Objective 2: To determine if serum and urine MMP-2 and MMP-9 levels differ in regards 
to the severity of OSA. 
Hypothesis 2: Serum and urine levels of MMP-2 and MMP-9 correlate with the severity 
of OSA. 
 
Objective 3: To verify if adult OSA patients with cardiovascular comorbidities have a distinct 
serum and urine MMPs level when compared to OSA patients without cardiovascular 
comorbidities. 
Hypothesis 3: Adult OSA patients with cardiovascular comorbidities have an increased serum 
and urinary MMPs level when compared to OSA patients without cardiovascular 
comorbidities. 
 
Format of the thesis 
 I will begin this thesis with a systematic review of articles on MMPs in OSA (Chapter 
3). A systematic review was prepared in order to critically appraise the existing studies on the 
topic, and it is included in the thesis to provide a thorough background on the topic and 
demonstrate  the gaps in knowledge that exist in this area. This systematic review represents 
the work I completed preparing for the research around the three objectives as part of my MSc 
program. The review has been published in 2019 in the journal Sleep Medicine Reviews [15]. 
Following this, I describe the methods used to address the three objectives. Finally, I discuss 
the results of the thesis in the context of the existing literature and draw conclusions. 
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In order to help explain potential associations observed around urinary MMP activities, 
kidney function and level of kidney injury was assessed. However, it can be considered 
a secondary outcome as it was not part of the original objectives. 
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  LITERATURE REVIEW 
Franczak A, Bil-Lula I, Sawicki G, Fenton M, Ayas N, Skomro R. Matrix metalloproteinases 
as possible biomarkers of obstructive sleep apnea severity - A systematic review. Sleep Med 
Rev 2019;46:9–16. DOI: 10.1016/j.smrv.2019.03.010. 
 
3.1 Summary 
Obstructive sleep apnea is an underdiagnosed sleep-related breathing disorder affecting 
millions of people. Recurrent episodes of apnea/hypopnea result in intermittent hypoxia 
leading to oxidative stress. Obstructive sleep apnea is considered an independent risk factor for 
cardiovascular disease but the exact pathophysiology of adverse cardiovascular outcomes of 
obstructive sleep apnea has not been fully elucidated. Matrix metalloproteinases (MMPs) have 
been associated with both oxidative stress and cardiovascular diseases. Hypoxic conditions 
were shown to influence MMP expression, secretion and activity. Moreover, matrix 
metalloproteinases contribute to ischemia/reperfusion injury. Therefore, action of matrix 
metalloproteinases can provide a possible molecular mechanism linking obstructive sleep 
apnea with oxidative stress and cardiovascular disease. The aim of this paper was to review the 
current evidence of association between matrix metalloproteinases and obstructive sleep apnea 
with focus on hypoxemia and severity of obstructive sleep apnea. 
 
Key words: obstructive sleep apnea, sleep disordered breathing, matrix metalloproteinase, 
oxidative stress, cardiovascular disease, systematic review 
 
Glossary of terms 
AHI – apnea-hypopnea index 
BMI – body mass index 
CIH – chronic intermittent hypoxia 
CRP – C-reactive protein 
CVD – cardiovascular disease 
ELISA – enzyme-linked immunosorbent assay 
IL-6 – interleukin 6 
MMPs – matrix metalloproteinases 
NF-κB – nuclear factor kappa B  
ODI – oxygen desaturation index 
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RDI – respiratory disturbance index 
ROS – reactive oxygen species 
siRNA – small interfering RNA (ribonucleic acid) 
SNP – single nucleotide polymorphism 
SpO2 – blood oxygen saturation 
SpO2 <90% - time of blood oxygen saturation below 90% 
 
3.2 Introduction 
3.2.1 Obstructive sleep apnea – clinical characteristics, prevalence and cardiovascular 
complications 
Obstructive sleep apnea (OSA) is the most common sleep-related breathing disorder. It is 
characterized by recurrent episodes of airflow cessation (apnea) or reduction (hypopnea), 
caused by the decrease of upper airway dilating muscle activity during sleep superimposed on 
a narrow upper airway. These abnormalities impair normal ventilation during sleep and result 
in hypoxemia and sleep fragmentation as a consequence of frequent respiratory-related arousals 
leading to poor sleep quality, daytime somnolence and adverse effects on quality of life [1]. 
Cognitive complaints, fatigue and mood disorders are frequently observed.  Furthermore, OSA 
is associated with worse work performance and higher risk of motor vehicle crashes [6]. 
OSA has been considered a major public health problem [48]. It affects all age groups 
but increases in prevalence with age. The prevalence of OSA is estimated as 13% among adult 
males and 5.6% among adult females [3]. OSA rates have been increasing worldwide along 
with the prevalence of obesity [49].  
Despite the high prevalence and increased social awareness of OSA, this disorder still 
remains under-diagnosed. OSA is a condition with an insidious onset which can contribute to 
its delayed diagnosis. Data from a Canadian cross-sectional survey showed that only 5.1% of 
those at higher risk for OSA reported being referred to a sleep laboratory [50]. The delay in 
diagnosis and treatment leads to development of numerous complications. It has been  shown 
that patients with untreated OSA are at higher risk of neurocognitive impairment, Alzheimer’s 
disease and a wide range of cardiovascular conditions [9,51] such as systemic and pulmonary 
hypertension, heart failure, atherosclerosis, coronary artery disease and stroke [52,53]. 
The mechanisms which have been suggested to contribute to these adverse outcomes include 
sympathetic nervous system activation, inflammation, endothelial dysfunction and oxidative 
stress [9].  
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3.2.2 OSA as model of chronic intermittent hypoxia 
The narrowing or collapse of upper airway is frequently associated with a repetitive 
transient decrease in arterial oxygen saturation [54]. Therefore, one of the hallmarks of OSA 
is CIH (chronic intermittent hypoxia). The hypoxic events and arousals can lead to sympathetic 
nervous system activation, which contributes to peripheral vasoconstriction and triggers an 
increase in arterial blood pressure and heart rate. Systemic hypertension can in turn promote 
cardiac hypertrophy, diastolic dysfunction and potentially lead to congestive heart failure. 
Furthermore, increased negative intra-thoracic pressure, caused by the airway occlusion and 
resultant increased respiratory effort, generates an additional mechanical stress (increases in 
both pre-load and after-load) on the heart resulting in progression of cardiac remodeling. In 
addition to vasoconstriction, hypoxia leads to oxidative stress, inflammation and endothelial 
dysfunction, all of which are important element of atherosclerosis development. The adverse 
effect of CIH on the cardiovascular system may be a reason of premature death of OSA 
patients, mainly by a greater risk of myocardial infarction [55]. 
The exact pathophysiology of the adverse consequences of OSA is not fully-understood 
and is likely multi-factorial. However, it has been hypothesised that matrix metalloproteinases 
(MMPs) may be an important marker of chronic intermittent hypoxia. 
 
3.2.3 Matrix metalloproteinases as markers of intermittent hypoxia 
MMPs are proteolytic enzymes, which take part in remodeling of extracellular matrix 
and have also been shown to have a biological action within the cell as well [38]. They are 
essential for the wide range of physiological processes; their dysregulation may contribute to 
development of pathological conditions including CVD (cardiovascular disease) [16]. They 
have been shown to play a role in development of dilated cardiomyopathy, cardiac remodeling 
after myocardial infarction and atherosclerotic plaque rupture [42]. Recent evidence suggests 
that MMPs contribute not only to long-term remodeling processes but also to acute ischemia-
reperfusion injury in the heart [44].  
MMPs are synthesized as inactive zymogens by inflammatory cells, fibroblasts and 
endothelium. They are activated by the disruption of bond between a cysteine thiol residue and 
the active zinc ion site. This can be achieved by two mechanisms. First, several proteases (such 
as plasminogen, kallikrein, tissue plasminogen activator, trypsin as well as MMPs themselves) 
can cause proteolysis of the propeptide domain. Secondly, reactive oxygen species (ROS) can 
directly change a protein conformation exposing catalytic site of MMP [45]. Oxidative stress 
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during ischemia/reperfusion or asphyxia  causes an increase in MMPs action and leads to 
adverse cardiovascular consequences [12–14]. Recurrent episodes of apneas/hypopneas in 
OSA cause a  desaturation-reoxygenation sequence that resembles ischemia/reperfusion injury 
which is associated with excessive production of reactive oxygen species (ROS) and 
upregulation of oxidative stress markers and impaired antioxidant capacity in OSA  [10]. In 
addition, the results of studies on human and animal cell cultures have shown that MMPs 
expression, secretion and activity are induced by hypoxic conditions [56,57], which resemble 
those present in OSA patients, thus suggesting a potential role of MMPs’ in OSA.  
ROS, generated during CIH, can directly activate MMPs. Moreover, the MMPs activity 
can also be affected at the transcriptional level. CIH-mediated NF-κB (nuclear factor kappa B) 
pathway activation is an example of such regulation [58,59]. NF-κB upregulates not only  
numerous inflammatory cytokines and adhesion molecules, but also plays a role in the 
regulation of MMPs transcription [17,60]. Bond et al. have also shown that NF-κB is necessary 
to upregulate MMPs secretion by vascular smooth muscle cells [60]. The activation of NF-κB 
along with MMPs action can be a molecular mechanism linking OSA with oxidative stress, 
inflammation and in turn cardiovascular complications. The potential modes of action of 
MMPs in response to chronic intermittent hypoxia are summarized in Figure 3.1. 
Moreover, some studies report different single nucleotide polymorphisms (SNP) in the 
promoter region of MMPs in OSA patients [61–63], which may influence MMPs expression. 
However, the results of these studies are inconsistent. It was shown that MMP-9 SNP 
(1562C/T) was associated with higher risk of OSA in Chinese [62], but not in Turkish 
population [63]. Moreover, another study in Turkish population showed that allele frequencies 
of MMP-9 1626C/T SNP significantly differ between OSA patients with CVD compared to 
those without CVD. However, MMP-9 genotype was not associated with MMP-9 level in 
serum [61]. MMP-2 SNP (-1306C/T) has not been shown to be associated with risk of OSA 
[62]. 
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Figure 3.1 Potential MMP (matrix metalloproteinases) modes of action in response to chronic 
intermittent hypoxia. 
CVD, cardiovascular disease; IL-6, interleukin 6; ROS, reactive oxygen species; TNF-α, tumor 
necrosis factor α. 
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3.3 The aim of the review 
OSA can be considered a model of chronic intermittent hypoxia (CIH). Therefore, 
based on several lines of aforementioned evidence that MMPs play a role in hypoxia and CVD, 
it could be hypothesized that MMPs can be biomarkers of severity of hypoxemia, severity of 
OSA and may potentially be useful biomarkers of cardiovascular complications in OSA.  
Considering the complexity of cardiovascular comorbidities in OSA, finding 
biomarkers which allow detection of patients at higher risk is a great challenge for sleep apnea 
research and clinical management. Although a lot of effort has already been expended in 
searching for possible biomarkers, the results are still inconclusive. Blood-based markers of 
inflammation (interleukin 6 (IL-6), C-reactive protein (CRP), high sensitivity CRP and tumor 
necrosis factor-α), hemodynamic cardiac stress (N-terminal-B-type natriuretic peptide), 
myocardial injury (cardiac troponins) as well as indicators of antioxidant capacity and 
oxidative stress (thioredoxin, superoxide dismutase, malondialdehyde) have been proposed 
[64–68]. In this paper, we have reviewed the available literature about MMPs in this regard. 
 
3.4 Methods 
This systematic review followed the Preferred Reporting Items for Systematic Reviews and 
Meta-Analysis PRISMA Checklist [69]. Our PICO question was: In patients with diagnosed 
moderate to severe OSA (P), will the severity of OSA (I) be associated with elevated levels of 
MMPs in biological samples (O) in comparison with patients without OSA or those with mild 
OSA (C)? Only studies involving human OSA subjects (adult and children) published in 
English were included. We have reviewed EMBASE (05/12/2018) and Medline (via Ovid – 
including in-process and other non-indexed citations; 05/12/2018) – see search details in 
Appendix A.  Duplicates were removed through EndNote, and then titles and abstracts were 
reviewed manually by two authors (AF, RS). After initial screening, 2 investigators (AF, RS) 
reviewed independently the full-text manuscripts. References from the retrieved manuscripts 
were verified manually by two authors (AF, RS) to see if we missed any articles suitable for 
inclusion in this review. The process for selecting studies is provided in the flow chart (see 
Figure 3.2). The study quality was assessed with the modified Newcastle-Ottawa Scale (see 
Appendix B). 
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Figure 3.2 Flow diagram. 
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3.5 Results 
Our search results revealed overall 249 articles. After excluding studies which did not meet our 
criteria (see Figure 3.2) 10 manuscripts were reviewed (see Table 3.1). All of these concerned 
MMP-9 and MMP-2. 
 
3.5.1 MMP-9 in adult OSA patients 
Our review identified 8 publications that addressed the question of MMP-9 levels and 
activity in adult OSA patients. In all those articles, MMP-9 was analyzed in blood (serum, 
plasma, monocytes isolated from peripheral blood). The vast majority of results (five out of 
eight) showed that an increased blood MMP-9 level was associated with OSA and its increase 
was more notable in patients with severe OSA [56,70–73].  
Tamaki et al. have shown that the production of MMP-9 by peripheral blood monocytes 
of patients with both severe and mild/moderate OSA was significantly higher compared to 
control; however there were no difference between severe and mild/moderate OSA [71]. 
Nevertheless, Bonanno et al. did not report any significant association between serum 
MMP-9 level and OSA, however, in severe OSA, a trend to increase MMP-9 level was 
observed [74]. Maeder et al. [75] and Volná et al. [76] also did not report any significant 
differences in blood MMP-9 concentrations in regards to OSA severity (defined by AHI 
(apnea-hypopnea index)).  
The results of the study carried out by Hopps et al. provided some evidence of 
association between MMPs and oxidative stress in OSA. In this study a positive correlation 
between plasma levels of MMP-9 and lipid as well as protein peroxidation markers was found 
[77]. ROS can activate MMPs and indeed, Tazaki et al. showed that serum MMP-9 activity 
was elevated in patients with OSA compared to controls. Moreover, that activity was positively 
correlated with AHI [72].  
A positive correlation between MMP-9 and level of hypoxemia expressed as ODI 
(oxygen desaturation index) and/or SpO2 <90% (time of blood oxygen saturation below 90%) 
was shown in five studies [56,70,72,73,76]. Moreover, a negative correlation between MMP-
9 and mean oxygen saturation was found [70,76]. All these results are in accordance with 
findings that hypoxic condition can induce MMP-9 expression, secretion and activity [56] 
which indicate that oxidative stress, one of the crucial factors of CVD, may contribute to 
pathophysiology of OSA by stimulation of MMPs action.  
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Bearing in mind that MMP-9 can be upregulated by pro-inflammatory cytokines, a 
positive correlation between serum levels of MMP-9 and IL-6 (interleukin 6) and TNF-α found 
in OSA patients by Tazaki et al. is not surprising  [72]. Also, Ye et al. found a positive 
correlation between serum MMP-9 concentration and CRP level [73]. Moreover, Wang et al. 
[56] suggested that MMP-9 may be a predictor of CVD in OSA patients. During up to five-
year long follow-up of 35 patients without hypertension, 12 of them developed hypertension 
and three patients had left ventricular hypertrophy. Increased serum level of MMP-9, OSA 
severity (defined by AHI) and decreased lowest SpO2 were risk factors for new hypertension 
onset. All patients who developed left ventricular hypertrophy had an elevated serum levels of 
MMP-9. 
In summary, the preponderance of evidence suggests that circulating MMP-9 level is 
increased in patients with OSA and this increase is related to OSA severity [56,70–73], 
inflammation [72,73] and/or severity of hypoxemia [56,70,72,73,76]. 
 
3.5.2 MMP-9 in OSA among children 
There is only one study concerning MMP-9 in children with OSA. Kaditis et al. [78] 
showed that plasma MMP-9 level was correlated with CRP and BMI (body mass index), but 
there was no association between MMP-9 and severity of OSA. The vast majority of children 
(92.5%) were less than 10 years old. The AHI ranged from <1 episode/hour in patients without 
OSA to approximately 3 episodes/hour in mild OSA and 13 episodes/hour in moderate-to-
severe OSA patients. The ODI ranged from 0.9±0.6 to 15.6±14.1 episodes/hour, depending on 
the OSA severity. There were no significant differences between MMP-9 level in children with 
and without OSA, which is in contrast to most studies in adults. This finding could be explained 
by the fact that children with OSA often do not have as advanced hypoxemia as adult patients. 
Therefore, the molecular CIH-dependent mechanisms of MMPs stimulation in children OSA 
patients may not be activated. The authors concluded that the primary reason for elevated 
MMP-9 level in blood of children with OSA may be inflammation which results from factors 
other than hypoxemia.  
 
3.5.3 MMP-2 in adult OSA patients 
Current literature on the subject of MMP-2 is more limited and inconclusive. Our search 
revealed only four published papers concerning MMP-2 in adults with OSA and no studies in 
children. MMP-2 was analyzed in serum or plasma in three manuscripts [70,74,76] and one 
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article investigated the presence of MMP-2 in superior pharyngeal constrictor muscle 
specimens (however, MMP-2 protein was not detectable [79]). Only one study [70] reported 
an increased MMP-2 plasma level in OSA patients; however, without any correlation with OSA 
severity (defined by AHI) [70]. Another  study showed no association between OSA and blood 
levels of MMP-2 [76].  Interestingly, Bonanno et al. reported that MMP-2 level was lower in 
patients with severe OSA (here defined as respiratory disturbance index (RDI)  > 30) compared 
to subjects with RDI < 30 [74]. In summary, the evidence linking MMP-2 and OSA severity is 
scarce with limited data in adults and no studies in children with OSA. 
 
3.6 Discussion 
OSA is the most common sleep-related breathing disorder, which still remains 
underdiagnosed [50]. It leads to numerous cardiovascular complications which affect quality 
and length of patients’ life [10]. Given that, early diagnosis is crucial to implement proper 
therapy early in the course of the disease to prevent adverse consequences related to OSA 
severity - decreasing incidence of CVD events among others. However, solely clinical criteria 
are insufficient to identify patients at higher risk for cardiovascular events. This review 
suggests that MMP-9 may be promising biomarker in this regard.  
The preponderance of evidence suggests an association between MMPs (particularly 
MMP-9) and severity of OSA. Five out of eight studies that examined relationship between 
MMP-9 and OSA showed that MMP-9 level was elevated in patients with OSA in comparison 
with patients without OSA or those with less severe OSA [56,70–73]. Additionally, another 
study [74] reported a trend to increase MMP-9 level in severe OSA, however, without statistical 
significance (this may have been due to the lack of statistical power). Moreover, data from the 
reviewed studies suggests that MMP-9 may be potentially an indicator of level of hypoxemia, 
as in a few studies MMP-9 level was found to  positively correlate with ODI and SpO2 <90% 
[70,72,73,76]. 
The literature on the subject of MMP-2 in OSA is limited to four papers, therefore 
drawing any conclusions about MMP-2 association with OSA is difficult. However, there is 
the strong evidence of association between MMP-2 and oxidative stress in animal studies [16–
18] and thus future studies of MMP-2 in larger samples of OSA patients should be considered, 
given the fact that recurrent episodes of apnea/hypopnea result in intermittent hypoxia and in 
turn lead to oxidative stress [10]. 
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3.6.1 Study limitations 
Our search has provided important insight into association between MMP level and 
OSA severity, however, the results of current literature on this subject are still preliminary. In 
most of the studies, sample sizes were small (N = 50-70), which may have affected statistical 
powers of the study and different indexes (AHI, RDI) were used to express OSA severity (see 
Table 3.1).  
Moreover, OSA definition varied across the studies. Most studies defined OSA by an 
AHI ≥ 5/hr, however, some used the cut-off of AHI ≥ 10/hr or RDI ≥ 5/hr (see Table 3.1). 
Some of the studies used 3% desaturation to score hypopnea [76,78], others 4% [71,73–75], 
while Hopps et al. used a 3% or 4% drop in oxygen saturation, depending on % in reduction of 
breathing [70]. Three of studies did not note the cut-off for oxygen desaturation at all 
[56,72,79]. 
Furthermore, only six of studies used the gold standard for OSA diagnosis (see Table 
3.1), and very few controlled for confounders. MMPs have been  shown to have an impaired 
pattern in various CVDs, inflammatory diseases and metabolic syndrome [42,80]. MMP levels 
may depend on age and gender [81]. However, in only four studies [71–73,78] the potential 
confounders (age, gender, BMI, CRP concentration [78]; BMI, age [71,73]; BMI, waist 
circumference, waist/hip ratio [72]) were adjusted for in the analysis. Although some authors 
tried to address presence of confounders in the study design  by excluding patients who have 
had CVD or systemic infections, CVD were often not well-defined [71,72,74,78] or limited to 
heart failure [75]. Two studies did not address the issue of confounding at all [70,77]. Hopps 
et al. [70] not only did not control for it, but  enrolled in the study group patients with OSA and 
CVD, whereas control subjects were free of medical illnesses which were however not defined 
in detail.  
Furthermore, majority of study designs were either cross-sectional or case-control in 
their design. Only one study was a cohort in its design to determine if MMP-9 level can be a 
predictor for CVD development and demonstrated possible role of MMP in development of 
CV complications [56]. However, numerous limitations of this study should be listed. First, 
sample size was small (n = 47), and cohort chosen for follow-up constituted only 35 subjects. 
Second, OSA diagnosis was based on cardiorespiratory study (which is not a gold standard). It 
is also not clear from the paper if patients enrolled for follow-up were free from CVD (if 
assuming so, it still remains unknown how CVD was defined). 
Last but not least, there are also some methodological limitations of reviewed studies. 
Only one study [72] used two techniques (enzyme-linked immunosorbent assay (ELISA) and 
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gelatin zymography) for MMP-9 measurement, whereas others used only one (ELISA or 
another immunoassay technique). It should be emphasized that ELISA and zymography differ 
significantly in regard to the principle of methodology. More precisely, immunoassay 
technique quantifies protein concentration based on reaction of antigen and antibody, whereas 
gelatin zymography is based on the gelatinolytic (proteolytic) activity of the enzyme and the 
latter one is more important from biological point of view. Moreover, in methods based on 
interaction of antigen and antibody (ELISA) there are many limitations associated with 
specificity and selectivity of the antibodies used for the detection of antigen, whereas 
zymography allows for detection of specific enzyme based on its catalytic activity and 
molecular weight [82,83]. 
Despite a number of limitations, the association between MMPs and OSA seems to be 
likely, especially in the light of biological plausibility. An elevated MMP-9 level in OSA 
patients with more severe disease compared to those with less severe or without OSA is in 
accordance with suggested contribution of oxidative stress and inflammation to OSA 
development [54], because MMPs’ expression, secretion and activity may be modulated by 
hypoxia and inflammation [17,56]. Keeping in mind these feasible links between OSA, 
oxidative stress, inflammation, CVD and MMPs (see Figure 3.1), MMPs seem to be promising 
proteins for identification OSA patients at higher risk of CVD. Apart from the above-
mentioned cohort study of Wang et al. [56], additional report showed that serum MMP-9 level 
was significantly increased in OSA patients with CVD (coronary artery disease, hypertension 
and cardiac arrythmia) compared to those without CVD [61]. 
The studies in animal models also provide the evidence on the CIH-modulated MMP 
response and its potential association with CVD. Some authors have shown that CIH induce 
cardiac fibrosis in rats. Fibrosis results from an imbalance in extracellular matrix turnover 
which can be explained by observed significant changes in MMP levels in hearts of rats 
subjected to CIH [17,84–86]. However, analogously to human studies, results regarding the 
direction of these changes are not consistent [17,84–86]. 
The observations from the animal studies cannot be directly applied to humans, 
considering the anatomical and biochemical differences between species and the limitations of 
animal models to mimic the human OSA pathophysiology. Only one model applied the airway 
obstruction which is an integral component of OSA [86]. Furthermore, MMPs were not 
analyzed in body fluids, but in cardiac tissue. Moreover, various time of CIH was applied which 
also can be an explanation of observed differences in direction of changes in MMP levels. Also, 
the effect of short-term hypoxia varies from the long-term effect [87] and in the above-
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mentioned papers the time of protocol varied from 7 days to 5 weeks with different pattern of 
hypoxia/normoxia cycles. 
However, the animal studies, similarly to the human ones reviewed in this paper, 
provide some evidence that CIH has an impact on MMP response. Due to MMP’s substrate 
specificity with respect to extracellular matrix proteins, it can lead to cardiac fibrosis and in 
consequence, CVD. Cardiac remodeling is associated with cardiac dysfunction which may 
manifest itself as malignant ventricular arrhythmias, heart failure and myocardial infarction 
complications [42], all of which have an increased prevalence in OSA patients. In addition, 
patients with OSA commonly develop left ventricular hypertrophy [88].  
Given MMPs possible contributions to OSA adverse cardiovascular consequences, 
MMPs may also become a therapeutic target. Wang et al. showed that doxycycline, 
administered to rats for four weeks while receiving CIH, attenuated atrial fibrosis induced by 
CIH by modulation of MMP-2 and MMP-9 expression [85]. In the studies on 
ischemia/reperfusion injury in rat hearts it was shown that doxycycline prevented MMP-2-
induced troponin I degradation and improved cardiac mechanical function [38,44]. 
Doxycycline, analogically to other studied MMP inhibitors such as o-phenanthroline and 
hydroxamates, inhibits MMPs non-selectively by chelating zinc ion in catalytic site of MMPs. 
Currently, doxycycline is the only clinically approved inhibitor of MMPs [45]. However, in 
the randomized controlled trial in patients undergoing coronary artery bypass graft surgery with 
cardiopulmonary bypass, doxycycline (20 mg) did not improve myocardial stunning following 
the surgery, despite the fact that the atrial MMP-2 activity was decreased. Authors suggested 
that higher dose of doxycycline should be considered in the next larger trials [89]. Lin et al. 
showed that MMP-2 siRNA (small interfering RNA), by specific inhibition of MMP-2 
expression and activity, led to protection of contractile function of isolated rat cardiomyocytes 
subjected to chemical ischemia [90]. Due to increasing interest in the molecular therapy and 
precision medicine, there is a growing potential for the use of MMP-2 siRNA in clinical trials 
[91]. 
In conclusion, there are plausible biological mechanisms linking an increase in MMP 
levels and OSA and the preponderance of evidence from this systematic review suggests that 
MMPs (especially MMP-9) is elevated in OSA patients. These studies however are limited by 
their study design, small subject number and lack of adjustment for confounders. Although 
there are a few negative studies, MMPs seem to be promising predictors of hypoxemia and 
severity of OSA. It is possible therefore that they may be useful markers of adverse 
cardiovascular outcomes in OSA which appear to be mediated by hypoxemia. However, the 
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results of studies published on this subject are inconclusive and, thus, further research is needed 
to delineate the exact role of MMPs in OSA, particularly in the subset of patients with CV 
complications. 
  Future studies should be performed in larger samples of both children and adult 
populations, should be cross-sectional and prospective in their design, should adequately 
control for confounders and must be adequately powered to detect a difference in MMP levels.  
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Practice Points 
Matrix metalloproteinases are important molecules in obstructive sleep apnea research, 
because: 
• Animal studies suggest involvement of MMP in models of CIH and their role in 
cardiovascular disease. 
• The majority of studies suggest increased MMP levels (MMP-9 in particular) in patients 
with obstructive sleep apnea. 
• The existing studies suggest presence of association between blood level of MMP-9 
and obstructive sleep apnea severity in adults. 
• Increased MMP levels in OSA patients may result from higher level of hypoxemia and 
therefore, MMPs could be a molecular mechanism linking OSA with oxidative stress 
and cardiovascular disease. 
• There is very limited literature on this subject in children. 
• There are no prospective studies evaluating the role of MMPs in predicting 
cardiovascular complications in OSA patients.  
• Existing studies suffer from methodological weaknesses, especially in their approach 
to handling confounding. 
 
Research Agenda  
• Future research should be aimed at delineating the role of matrix metalloproteinases in 
obstructive sleep apnea with focus on their associations with hypoxemia, severity and 
cardiovascular outcomes of the disease.  
• Larger sample sizes are required in future studies. 
• The current gold standard (i.e. in-lab PSG) should be used for diagnosis of OSA. 
• Severity of the disease should be categorized according to American Academy of Sleep 
Medicine criteria. 
• Future studies should be long term and must be powered to detect difference in MMP 
levels. 
• More studies of MMP in children with OSA are needed. 
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Table 3.1 Overview of studies of MMPs in OSA. 
Author, 
reference 
number 
Study 
design 
 
Number 
of 
subjects 
Type of 
diagnostic 
study * 
Type of 
MMPs 
Material 
OSA 
definition 
Compared 
groups 
The direction of 
changes in MMP 
level** 
 
Comment 
MMP-2 MMP-9  
Bonanno 
et al. [74] 
Cross-
sectional 
50 Type 1 MMP-2 
MMP-9 
 
Serum RDI ≥ 5  Severe (RDI>30) 
vs non-severe 
↓ ↑ # 
 
 
 
Dantas et 
al. [79] 
 
Case-control 51 
 
 
Type 1 MMP-1 
MMP-2 
Superior 
pharyngeal 
constrictor 
muscle 
specimens 
AHI ≥ 5 Cases vs controls MMP-2 
was not 
detectable 
(IHC). 
 Variable MMP-1 
expression (IHC) 
within the same muscle 
fiber and 
between patients. 
Hopps et 
al. [70] 
Case-control 79 
 
 
Type 3 MMP-2 
MMP-9 
Plasma AHI ≥ 5 Severe (AHI 
>30) vs controls 
↑ 
 
↑ 
 
 
MMP-9 positively 
correlated with AHI, 
ODI and negatively 
correlated with mean 
SpO2. 
Severe vs 
mild/moderate 
N  ↑ 
 
Mild/moderate 
(5≤AHI<30) vs 
controls 
↑ 
 
↑ 
 
Kaditis et 
al. [78] 
Case-control 106 
 
Type 1 MMP-9 Plasma AHI ≥ 1 Moderate/severe 
(AHI>5) vs mild 
(1≤AHI<5) vs 
control 
 N Study in children. 
Maeder et 
al. [75] 
Cross-
sectional 
 
71 Type 1 or 
type 3 
MMP-9 Plasma AHI > 5 Moderate/severe 
(AHI≥15) vs 
mild/no 
(AHI<15) 
 N  
Tamaki et 
al. [71] 
Case-control 
 
46 
 
 
Type 1 MMP-9 Blood 
monocytes 
AHI ≥ 10 Severe (AHI≥30) 
vs controls 
 ↑ 
 
 
Mild/moderate 
(AHI<30) vs 
controls 
 ↑ 
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Tazaki et 
al. [72] 
Case-control 
 
62 
 
Type 1 MMP-9 Serum AHI ≥ 5 Moderate/severe 
(AHI≥20) vs 
controls 
 ↑ 
 
MMP-9 level and 
activity positively 
correlated with AHI 
and SpO2 <90%. Moderate/severe 
vs mild 
(5<AHI<20) 
 ↑ 
 
Mild vs controls  ↑ 
Volná et 
al. [76]  
Cross-
sectional 
51 Type 3 MMP-2 
MMP-9 
Serum AHI > 5 Severe vs 
moderate vs mild 
vs controls 
N N MMP-9 level positively 
correlated with ODI 
and SpO2 <90% and 
negatively correlated 
with mean SpO2. 
 
Wang et 
al. [56]  
 
Cohort 
retrospective 
47 
 
 
Type 3 MMP-9 Serum AHI ≥ 5 Moderate 
(15≤AHI<30) vs 
mild 
(5≤AHI<15) 
 ↑ 
 
MMP-9 level positively 
correlated with AHI, 
ODI and mean atrial 
pressure. 
Severe (AHI>30) 
vs mild 
 ↑ 
 
Ye et al. 
[73] 
Case-control 76 Type 1 MMP-9 Serum AHI ≥ 5 Moderate/severe 
(AHI≥20) vs 
controls 
 ↑ 
 
MMP-9 level positively 
correlated with AHI 
and SpO2 <90%. 
Moderate/severe 
vs mild 
(5≤AHI<20) 
 ↑ 
 
Mild vs controls  ↑ 
Legend: AHI, apnea-hypopnea index; CRP, C-reactive protein; IHC immunohistochemical analysis; MMP, matrix metalloproteinase; 
ODI, oxygen desaturation index; OSA, obstructive sleep apnea; RDI, respiratory disturbance index; SpO2, blood oxygen saturation; SpO2 
<90%, time of blood oxygen saturation below 90%; *according to American Academy of Sleep Medicine criteria; ** MMP concentration, 
unless otherwise noted; ↑ increase; ↓ decrease; N no difference; # without statistical significance
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 METHODOLOGY 
4.1  Data sources 
The study is a part of a large multi-center Canadian trial currently performed through the 
Canadian Sleep and Circadian Network (CSCN), which started data collection in  2016. Subjects  
were recruited among patients referred to the Sleep Disorders Center (Saskatoon City Hospital, 
Saskatchewan, Canada) for polysomnography (PSG). Written consent for participation in the study 
was obtained. Subjects completed a detailed medical and sleep questionnaire, were assessed for 
OSA by in-lab PSG, and provided blood and urine samples. This study was approved by the 
University of Saskatchewan Ethics Committee.  
The database was accessed through REDCap (Research Electronic Data Capture) 
(https://redcap.usask.ca/redcap/). The database includes detailed physiologic data from 
polysomnography (e.g. AHI, ODI – oxygen desaturation index), detailed demographic and 
phenotypic data (e.g. age, gender, body mass index), and medical history including co-existing 
medical disorders such as cardiovascular diseases among others. 
 
4.2 Materials 
Blood and urine samples were collected from all patients in the morning after in-lab PSG. 
Collection and treatment of blood samples have been performed according to SOP (Packet B) of 
the Center for Advanced Research in Sleep Medicine (CARSM) Sleep Research Biobank. In order 
to get serum, the Z Serum Clot Activator Sep tube (Greiner bio-one Vacuette Ref # 456018 or the 
equivalent) was used. The collection tube contains a clot activator (silicone dioxide) and a gel 
barrier in the base of the tube which separate the serum and the blood cells during centrifugation. 
After collection, the tubes were kept on a rack at room temperature for about 30 minutes (before 
centrifuging) to allow clotting of blood. Later on, the tubes were centrifuged at 3000 RPM 
(rotations per minute) for 10 minutes at room temperature. Next, serum was collected, aliquoted 
and frozen at - 80°C for later analysis.  
Urine samples were centrifuged at 4000 RPM for 10 minutes at 4°C, collected without 
sediment, aliquoted and frozen at - 80°C. 
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4.3 Study groups 
Subjects with and without OSA have been included in this study. All subjects underwent 
polysomnography, and were divided according to OSA severity as per American Academy of 
Sleep Medicine criteria [26]. Severity was established based on apnea/hypopnea index (AHI): 
number of events (apneas + hypopneas) per hour of sleep. Apnea was defined as a cessation of 
breathing for a minimum of 10 seconds. Hypopnea was defined as a decrease of airflow for more 
than 10 seconds associated with oxygen desaturation of 3% or an arousal.  
 
Based on the above definitions the following study groups were defined: 
1. Patients referred for PSG who were not diagnosed with OSA (AHI < 5) – controls. 
2. Patients with mild OSA (5 ≤ AHI < 15) 
3. Patients with moderate OSA (15 ≤ AHI < 30) 
4. Patients with severe OSA (AHI ≥ 30) 
 
Additionally, patients were divided according to cardiovascular status (with or without CVD). 
Cardiovascular comorbidities were herein defined as history of physician diagnosed arterial 
hypertension, coronary artery disease, heart failure, stroke and atrial fibrillation. Presence of these 
comorbidities has been verified by thorough medical records review.  
 
4.4 Methods 
4.4.1 Polysomnography, anthropometrics and medical history 
In-lab PSG was obtained using Sandman v.10, using the following channels: EEG, R and 
L EOG, chin EMG, airflow (pressure transducer and thermocouple), respiratory effort, anterior 
tibialis EMG, body position, EKG and oxygen saturation. PSG recordings were scored by a 
registered PSG technologist to the results of the study. 
All patients self-completed a questionnaire which asked about socio-demographics and 
medical history, including a history of hypertension and physician diagnosed cardiovascular 
disease (coronary artery disease, heart failure, stroke, atrial fibrillation).  
Body mass index (BMI) was calculated from height and weight measurements taken while 
patients were wearing light clothing. 
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4.4.2 MMP-2 and MMP-9 activity assay (zymography) 
Principles of the method: Gelatin zymography is a combination of two techniques: 
1. Protein resolution in electric field. 
2. Detection of protein and its measurement. 
 
 Samples were mixed with non-reducing sample loading buffer (in a ratio 3:1 (v/v)), and 
twenty µl of such prepared samples were applied to 8% polyacrylamide gels copolymerized with 
2 mg/mL gelatin. The composition of sample loading buffer was: 0.5 M Tris-HCl containing 0,4% 
SDS (pH 6.8) - 70% (v/v), glycerol - 30% (v/v), SDS 10% - (w/v), bromophenol blue - 0.012% 
(w/v), ddH2O. 
After electrophoresis (150V; 4°C), gels were rinsed in 2.5% Triton X-100 (3 times for 20 
min) to remove SDS in order to gelatinases’ renaturation. Then, the gels were washed in the 
incubation buffer for 10 min at room temperature. The composition of the incubation buffer was: 
50 mM Tris–HCl pH 7.4, 5 mM CaCl2, 150 mM NaCl, 0.05% NaN3. The gels were incubated in 
the incubation buffer overnight at 37°C (24h for serum, and 48h for urine) in order to let the MMPs 
degrade gelatin embedded in the gel.  
After incubation, gels were stained in staining solution (0.05% Coomassie Brilliant Blue 
R-250, 25% methanol, 10% acetic acid) for 2 h and then destained in destaining solution (4% 
methanol, 8% acetic acid). Gelatinolytic activities were observed as bright bands against the 
Coomassie stained background.  
Zymograms were scanned using VersaDoc 5000 (BioRad), and the band intensities were 
analyzed by Quantity One software v. 4.6.6 (BioRad). MMP activities were expressed in arbitrary 
units (AU) as activity per 20 µl of either serum or urine. 
Internal standard was used for normalization of MMPs level. Purified human MMP-2 
(MMP-2, active, human, recombinant, mouse cells, Millipore) was used as MMP-2 reference 
standard. To identify the MMPs based on their molecular weight, the molecular-weight size marker 
(Color Prestained Protein Standard, Broad Range, BioLabs,) was loaded to every gel.  
The desired concentration of samples was established by performing gelatin zymography 
of different concentration of urine/serum samples and choosing the one that allows for detection 
of MMP activity. Urine samples were concentrated 10 times (Amicon Ultra 30K, Millipore). 
Serum samples were diluted 20 times with deionized water. 
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4.4.3 Measurement of kidney function and level of kidney injury 
4.4.3.1 Kidney function 
Renal function was measured with estimated glomerular filtration rate (eGFR). Glomerular 
filtration rate was estimated from serum creatinine, age, sex, and race using the CKD-EPI (Chronic 
Kidney Disease Epidemiology Collaboration 2009) equation [92], recommended by The National 
Kidney Foundation. 
The eGFR values greater than or equal to 90 mL/min/1.73 m2 were considered as normal, 
60-89 mL/min/1.73 m2 as mildly decreased, 45-59 mL/min/1.73 m2 as mildly to moderately 
decreased, 30-43 mL/min/1.73 m2 as moderately to severely decreased, 15-29 mL/min/1.73 m2 as 
severely decreased, and <15 mL/min/1.73 m2 as kidney failure. 
 
4.4.3.2 Glomerular injury 
Glomerular injury was measured by urinary albumin-to-creatinine ratio (ACR). The 
albuminuria categories were as followed: normal to mildly increased < 3 mg/mmol; moderately 
increased 3-30 mg/mmol; severely increased > 30 mg/mmol. 
 
4.4.3.3 Tubular injury 
Neutrophil gelatinase-associated lipocalin (NGAL) – marker of tubular kidney injury – was 
measured with commercially available ELISA test (Lipocalin-2 (NGAL) Human ELISA KIT, 
Abcam, ab119600). 
NGAL is considered useful in diagnosis of both acute kidney injury (AKI) and chronic 
kidney disease (CKD). Its levels correlate with severity of renal impairment, expressing the degree 
of tubular damage in response to different stress stimuli such as oxidative stress [93].  
The assay was performed according to the manufacturer’s instruction (Lipocalin-2 
(NGAL) Human ELISA KIT, Abcam, ab119600). Briefly, urinary NGAL interacted with 
monoclonal antibodies specific for NGAL that have been coated onto the wells. Next, biotinylated 
polyclonal anti-NGAL antibodies were added, followed by their binding with ABC complex 
(Avidin-Biotin-Peroxidase Complex). The substrate solution was then used to visualize the HRP 
enzymatic reaction. The concentration of NGAL was proportional to the absorbance (λ = 450nm) 
of the colored product. 
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4.4.4 Statistical analysis 
Data analysis was performed using SPSS version 25. Analyses were two-sided with an 
alpha of 0.05. Descriptive statistics are presented as mean ± SD (standard deviation) and/or median 
with interquartile range (IQR) for continuous variables; and frequencies and proportions for 
categorical variables.  
Objective 1: For this analysis, the primary independent variable was presence or absence of OSA. 
The dependent variables were level of MMP-2 and MMP-9.The independent-samples t test (if 
assumption of normality was met) or Mann-Whitney-Wilcoxon test (if data set was not normally 
distributed) was performed in order to compare two groups.  
Objective 2: The primary independent variable was severity of OSA. The dependent variables were 
level of MMP-2 and MMP-9. ANOVA or the non-parametric equivalent (Kruskal-Wallis test) was 
used to compare more than two independent groups. In order to adjust for potential confounders, 
multiple linear regression was performed. The univariable analysis was conducted to determine 
the candidate variables for the multivariable models. This included assessment of correlation 
between MMP levels and apnea/hypopnea index using the Pearson correlation coefficient. 
Variables with p-value < 0.25 along with other potentially clinically important covariates were 
selected for the multiple linear regression. Log transformation of variables was used if the 
assumptions were not met. 
Objective 3: For this analysis, only those participants with OSA were included. The primary 
independent variable was presence of cardiovascular comorbidity and the dependent variables 
were MMP-2 and MMP-9. The independent-samples t test (if assumption of normality was met) 
or Mann-Whitney-Wilcoxon test (if data set was not normally distributed) was performed in order 
to compare two groups. 
 
Finally, kidney function and kidney injury were assessed to help explain potential associations 
observed around urinary MMP activities. The primary independent variable was severity of OSA, 
and the dependent variables were eGFR, ACR and NGAL. ANOVA or the non-parametric 
equivalent (Kruskal-Wallis test) was used to compare more than two independent groups. Then, 
urinary MMP-2-to-creatinine was compared between groups with normal to mildly increased 
albuminuria and moderately to severely increased albuminuria. The Mann-Whitney-Wilcoxon test 
was performed in order to compare these two groups. In order to adjust for potential confounders, 
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multiple linear regression was performed. The univariable analysis was conducted to determine 
the candidate variables for the multivariable models. Variables with p-value < 0.25 along with 
other potentially clinically important covariates were selected for the multiple linear regression. 
Log transformation of variables was used if the assumptions were not met. 
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 RESULTS 
5.1 Comparisons of adult OSA patients and controls 
A total of 150 patients were studied. Their demographic, anthropometric, and 
polysomnographic characteristics, stratified by OSA status, are presented in Table 5.1. There was 
no difference in the sex distribution between OSA and control patients (58.1% and 46.2% were 
males, respectively). Patients with OSA were older (56.3 ± 12.0 vs 47.2 ± 12.5 years; p=0.001) 
and had significantly higher weight (101.3 ± 26.9 vs 83.5 ± 15.4 kg; p=0.002) and body mass index 
(34.2 ± 7.7 vs 28.4 ± 4.5 kg/m2; p<0.001) compared to control patients. By definition, AHI was 
higher in patients with OSA than in control patients (33.4 ± 29.2 vs 2.8 ± 1.4 events/h). The 
prevalence of CVD was significantly higher in OSA compared to control patients (54.0% vs 
19.2%; p=0.001). 
MMP activities are presented in Table 5.2. Serum MMP-2 activity was significantly higher 
in patients with OSA than in controls (p = 0.029; Figure 5.1A). 
 Although urinary MMP-2 activity in OSA patients was higher than in controls, the 
difference was not statistically significant (p = 0.129; Figure 5.1B). 
 Mean activities of MMP-9 for both serum and urine were higher in OSA patients compared 
to control, however the differences were not shown to be statistically significant (Figure 5.1C-D). 
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Table 5.1 Baseline characteristics of subjects stratified by OSA status. 
 Control (N = 26) OSA (N = 124) p-value 
Sex: male  12 (46.2%) 72 (58.1%) 0.266 
Age (years) 47.2 ± 12.5 56.3 ± 12.0 0.001 
Weight (kg) 83.5 ± 15.4 101.3 ± 26.9 0.002 
Height (m) 171.40 ± 8.74 171.9 ± 9.44 0.820 
BMI (kg/m2) 28.4 ± 4.5 34.2 ± 7.7 <0.001 
AHI (n/hr) 2.8 ± 1.4 33.4 ± 29.2 < 0.001 
ODI (n/hr) 3.97 ± 3.67 35.2 ± 33.4 < 0.001 
CVD occurrence: yes 5 (19.2%) 67 (54%) 0.001 
Type 2 diabetes: yes 1 (3.8%) 19 (15.3%) 0.201 
Data are presented as mean ± SD or frequencies (%). AHI, apnea/hypopnea index per hour of 
sleep; BMI, body mass index; CVD defined as: arterial hypertension, coronary artery disease, heart 
failure, stroke and atrial fibrillation; ODI, oxygen desaturation index (3%) per hour of sleep. 
Comparisons were performed by using the independent-samples t test or Chi-square test. 
 
  
Table 5.2 Comparison of MMPs activity between patients with OSA and Controls. 
 
Control OSA 
p value median (25th–75th percentile) 
mean (95% CI) 
MMP-2 serum 
134.9 (92.7 – 185.7) 
143.1 (115.8 – 170.4) 
176.2 (104.7 – 298.2) 
304.7 (210.4 – 399.0) 
0.029 
MMP-2 urine 
0.037 (0.005 – 0.117) 
0.106 (0.040 – 0.172) 
0.075 (0.010 – 0.320) 
0.284 (0.189 – 0.378) 
0.129 
MMP-9 serum 1100 (240 – 3182) 
1800 (1037 – 2564) 
928 (430 – 2287) 
2381 (1533 – 3229) 
0.783 
MMP-9 urine 0.11 (0.00 – 0.70) 
1.93 (0.00 – 4.24) 
0.36 (0.00 – 3.40) 
7.37 (4.43 – 10.30) 
0.084 
Comparisons were performed by using the Mann-Whitney-Wilcoxon test. 
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Figure 5.1 MMP activities in patient with OSA and controls. 
Comparison of MMP activities between patients with and without OSA: serum MMP-2 (A), 
urinary MMP-2 (B), serum MMP-9 (C), urinary MMP-9 (D). OSA – obstructive sleep apnea; *p 
< 0.05 vs control; mean, error bars: 95% confidence interval. 
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5.2 Comparisons in relation to the severity of OSA 
Characteristics of subjects, stratified by OSA severity, are shown in Table 5.3. There were 
no differences in sex and height distribution between the groups. The patients with more severe 
OSA tended to be heavier (weight, BMI) than those with less severe disease or the controls. There 
was a significant difference in prevalence of CVD among the groups. Severe OSA cases had high 
prevalence of CVD (63.8%), in both mild and moderate OSA groups the prevalence of CVD was 
approximately 48%, and in control group it was only 19.25% (p = 0.004). 
MMP activities in relation to OSA severity differ for MMP-2 in serum, and MMP-9 in both 
serum and urine (Figure 5.2A-D, Table 5.4). 
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Table 5.3 Characteristics of subjects stratified by OSA categories. 
  
Control  
(N = 26) 
 
Obstructive sleep apnea 
p-
value 
Mild 
(N = 43) 
Moderate 
(N = 34) 
Severe 
(N = 47) 
Sex: male 12 (46.2%) 20 (46.5%) 21 (61.8%) 31 (66.0%) 0.176 
Age (years) 47.2 ± 12.5 57.7 ± 12.0 * 55.6 ± 12.5 * 55.5 ± 11.8 * 0.006 
Weight (kg) 83.6 ± 15.4 91.7 ± 15.9 96.9 ± 19.6 113.1 ± 34.4 *#⸹ < 
0.001 
Height (m) 171.4 ± 8.7 171.1 ± 8.8 171.6 ± 10.4 172.7 ± 9.4 0.869 
BMI (kg/m2) 28.4 ± 4.5 31.3 ± 5.1 32.9 ± 5.8 37.7 ± 9.5 *#⸹ < 
0.001 
AHI (n/hr) 2.8 ± 1.4 9.3 ± 2.9 22.0 ± 4.6 63.7 ± 26.1 < 
0.001 
ODI (n/hr) 3.97 ± 3.67 10.36 ± 4.35 23.03 ± 7.30 66.74 ± 34.98 < 
0.001 
CVD 
occurrence: 
yes 
5 (19.2%) 21 (48.8%) 16 (47.1%) 30 (63.8%) 0.004 
Hypertension: 
yes 
5 (19.2%) 15 (34.9%) 13 (38.2%) 28 (59.6%) 0.006 
Diabetes type 
2: yes 
1 (3.8%) 4 (9.3%) 5 (14.7%) 10 (21.3%) 0.170 
Data are presented as mean ± SD or frequencies (%). * p<0.05 vs control group; # p<0.05 vs mild 
OSA; ⸹ p<0.05 vs moderate OSA. BMI, body mass index; CVD defined as: arterial hypertension, 
coronary artery disease, heart failure, stroke and atrial fibrillation. 
Comparisons were performed by using one-way ANOVA or Chi-square test. 
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Figure 5.2 MMP activities in regards to OSA severity. 
Comparisons for serum MMP-2 (A), urinary MMP-2 (B), serum MMP-9 (C), urinary MMP-9 (D). 
OSA – obstructive sleep apnea; *p < 0.05 vs control; mean, error bars: 95% confidence interval. 
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Table 5.4 MMPs activity according to OSA severity. 
 
 
Non-OSA 
(N = 26) 
Mild 
(N = 43) 
Moderate 
(N = 34) 
Severe 
(N = 47) 
p-value 
 
Median (25th–75th percentile) 
Mean (95% CI) 
MMP-2 serum 
135 (93 – 186) 
143 (116 – 170) 
180 (100 – 282) 
235 (167 – 303) 
133 (90 – 198) 
215 (133 – 297) 
229 (127 – 368) * ⸹ 
434 (198 – 669) 
0.003 
MMP-2 urine 
0.04 (0.01 – 0.12) 
0.11 (0.04 – 0.17) 
0.10 (0.01 – 0.32) 
0.24 (0.14 – 0.35) 
0.10 (0.02 – 0.34) 
0.22 (0.11 – 0.33) 
0.06 (0.01 – 0.28) 
0.37 (0.15 – 0.58) 
0.475 
MMP-9 serum 
1100 (240  – 3182) 
1800 (1037 – 2564) 
1230 (594 – 2316) 
2400 (1249 – 3551) 
573 (211 – 1510) # 
951 (605 – 1297) 
950 (540 – 2480) ⸹ 
3398 (1431 – 5364) 
0.039 
MMP-9 urine 
0.11 (0.00 – 0.70) 
1.93 (0.00 – 4.24) 
0.390(0.00 – 5.05) 
6.70 (2.31 – 11.09) 
0.05 (0.00 – 1.50) 
5.84 (0.18 – 11.51) 
0.84 (0.04 – 3.75) * ⸹ 
9.04 (3.55 – 14.53) 
0.028 
*p<0.05 vs control group; # p<0.05 vs mild OSA; ⸹ p<0.05 vs moderate OSA. Comparisons were performed by using Kruskal-Wallis 
test. 
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5.2.1 MMP-2 activity 
The highest serum MMP-2 activity was observed in patients with severe OSA. Serum 
MMP-2 activity in patients with severe OSA was significantly higher than in those with moderate 
OSA and controls (Figure 5.2A, Table 5.4).  
Simple linear regression showed statistically significant associations with MMP-2 activity 
in serum for AHI (p = 0.001; Figure 5.3A), ODI (p = 0.004; Figure 5.3B), and age (p = 0.023) 
(Table 5.5). The association between MMP-2 and AHI (Model 1) as well as MMP-2 and ODI 
(Model 2) persisted even after adjustment for age, sex, BMI, and CVD (Table 5.6). 
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Figure 5.3 Linear regression of ln MMP-2 and AHI (A) and ODI (B) in study subjects. 
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Table 5.5 Crude linear regression analysis of ln MMP-2 activity in serum on risk factors and other 
potentially important covariates. 
Variable r Parameter 
estimate (SE) 
p-value 
AHI 0.286 0.008 (0.002) < 0.001 
ODI 0.246 0.006 (0.002) 0.003 
Age 0.203 0.014 (0.005) 0.013 
Sex (reference is male) 
Female 
 
0.088 
 
-0.150 (0.140) 
 
0.283 
BMI 0.122 0.014 (0.009) 0.138 
CVD (reference is No) 
Yes 
 
0.148 
 
0.250 (0.138) 
 
0.072 
WBC 0.003 -0.001 (0.039) 0.973 
 
 
Table 5.6 Results from multiple linear regression analysis with serum MMP-2 as the outcome. 
Variable Model 1 Model 2 
Parameter 
estimate (SE) 
p-value Parameter 
estimate (SE) 
p-value 
Risk factor of primary interest 
AHI 
ODI 
    
0.008 (0.003) 0.004   
  0.006 (0.002) 0.017 
Age 0.012 (0.006) 0.046 0.012 (0.006) 0.034 
Sex (reference is male) 
Female 
 
-0.087 (0.135) 
 
0.519 
 
-0.122 (0.136) 
 
0.368 
BMI 0.001 (0.010) 0.958 0.003 (.010) 0.778 
CVD 0.083 (0.146) 0.570 0.082 (0.147) 0.580 
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5.2.2 MMP-9 activity 
MMP-9 activity in serum (p = 0.039) and MMP-9 activity in urine (p = 0.028) differed 
significantly between groups. MMP-9 activity in serum was significantly lower in patients with 
moderate OSA compared to severe OSA and mild OSA. 
Simple linear regression showed statistically significant associations with MMP-9 activity 
in serum for AHI (p = 0.043), ODI (p = 0.027), white blood cells (WBC) count (p < 0.001l; Figure 
5.4) and age (p = 0.049) (Table 5.7). Serum MMP-9 activity was associated with WBC count, 
independently of AHI/ODI, age, sex, BMI and CVD (Table 5.8). 
In urine, MMP-9 activity was significantly higher in severe OSA patients than in moderate 
OSA patients and controls. 
 
 
 
 
Figure 5.4 Linear regression of ln MMP-9 and WBC (white blood cell) count.
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Table 5.7 Crude linear regression analysis of ln MMP-9 activity in serum on risk factors and other 
potentially important covariates. 
Variable r Parameter 
estimate (SE) 
p-value 
AHI 0.165 0.008 (0.004) 0.043 
ODI 0.181 0.007 (0.003) 0.027 
WBC 0.454 0.358 (0.067) < 0.001 
Age 0.161 -0.017 (0.009) 0.049 
Sex (reference is male) 
Female 
 
0.037 
 
-0.101 (0.223) 
 
0.652 
BMI 0.183 0.033 (0.014) 0.025 
CVD (reference is No) 
Yes 
0.012 0.033 (0.221) 0.881 
 
 
Table 5.8 Results from multiple linear regression analysis with ln serum MMP-9 as the outcome. 
Variable Model 1 Model 2 
Parameter 
estimate (SE) 
p-value Parameter 
estimate (SE) 
p-value 
WBC 0.310 (0.079) < 0.001 0.300 (0.081) < 0.001 
AHI 
ODI 
0.008 (0.005) 0.132  
0.005 (0.004) 
 
0.226 
Age -0.014 (0.011) 0.191 -0.013 (0.011) 0.215 
Sex (reference is male) 
Female 
 
-0.235 (0.238) 
 
0.327 
 
-0.264 (0.238) 
 
0.270 
BMI -0.011 (0.023) 0.631 -0.005 (0.024) 0.851 
CVD (reference is No) 
Yes 
 
0.018 (0.262) 
 
0.944 
 
0.021 (0.264) 
 
0.937 
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5.3 Comparisons in regards to cardiovascular disease occurrence 
OSA patients with and without CVD did not differ in regards to sex distribution, weight, 
height, BMI, and polysomnographic parameters (Table 5.9). The groups differed only in regards 
to age (52.2 ± 10.8 vs 59.7 ± 12.0 for Non-CVD and CVD, respectively). 
There were no differences in MMP-2 and MMP-9 activities between patients with and 
without CVD (Table 5.10, Figure 5.5A-D). 
 
 
 
Figure 5.5 MMP activities in regards to cardiovascular disease occurrence. 
Comparisons for serum MMP-2 (A), urinary MMP-2 (B), serum MMP-9 (C), urinary MMP-9 (D). 
OSA – obstructive sleep apnea; CVD – cardiovascular disease; *p < 0.05 vs Non-CVD; mean, 
error bars: 95% confidence interval. 
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Table 5.9 Baseline characteristics of subjects stratified by CVD status. 
 Non-CVD (N = 57) CVD (N = 67) p-value 
Sex: male 32 (56.1%) 40 (59.7%) 0.689 
Age (years) 52.2 ± 10.8 59.7 ± 12.0 < 0.001 
Weight (kg) 98.5 ± 24.9 103.6 ± 28.4 0.299 
Height (m) 172.5 ± 10.1 171.3 ± 8.9 0.489 
BMI (kg/m2) 32.9 ± 6.9 35.2 ± 8.3 0.094 
AHI (n/hr) 32.3 ± 31.3 34.6 ± 27.6 0.692 
ODI (n/hr) 33.1 ± 32.5 37.0 ± 34.3 0.513 
Data are presented as mean ± SD or frequencies (%). AHI, apnea/hypopnea index per hour of 
sleep; BMI, body mass index; CVD defined as: arterial hypertension, coronary artery disease, heart 
failure, stroke and atrial fibrillation; ODI, oxygen desaturation index (3%) per hour of sleep. 
Comparisons were performed by using the independent-samples t test or Chi-square test 
 
 
 
Table 5.10 MMP activity in OSA patients with and without cardiovascular disease (CVD). 
 
OSA 
p-value 
Non-CVD CVD 
median (25th–75th percentile) 
mean (95% CI) 
MMP-2 serum 
167 (89 – 277) 
242 (178 – 306) 
185 (120 – 332) 
358 (191 – 525) 
0.176 
MMP-2 urine 
0.06 (0.01 – 0.26) 
0.17 (0.10 – 0.24) 
0.12 (0.01 – 0.47) 
0.38 (0.21 – 0.55) 
0.239 
MMP-9 serum 
950 (458 – 2288) 
3174 (1406 – 4942) 
905 (421 – 2286) 
1706 (1232 – 2180) 
0.944 
MMP-9 urine 
0.35 (0.01 – 3.02) 
7.52 (3.10 – 11.9) 
0.47 (0.00 – 3.98) 
7.23 (3.20 – 11.26) 
0.804 
Comparisons were performed by using the Mann-Whitney-Wilcoxon test. 
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Serum MMP-2 activity differed between groups at different OSA severity in patients with 
CVD (p = 0.029), not in those without CVD (p = 0.217). Severe OSA patients with CVD had 
significantly higher serum MMP-2 level compared to the controls; which was not observed in 
patients without CVD (Figure 5.6). 
The associations found between MMP-2 and AHI (Model 1) as well as MMP-2 and ODI 
(Model 2) (Table 5.6; Figure 5.3), when stratified by CVD, remained significant only for patients 
with CVD, not for those without CVD (Table 5.11). 
 
 
 
 
 
Figure 5.6 Serum MMP-2 activity in regards to OSA severity and CVD status. 
Mild and moderate groups were merged as there were no differences between them in regards to 
their demographic and anthropometric characteristics (Table 5.3), and serum MMP-2 level 
(Table 5.4, Figure 5.2). 
*p < 0.05 vs control; mean, error bars: 95% confidence interval. 
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Table 5.11 Results from multiple linear regression analysis with ln MMP-2 in serum as the 
outcome, stratified by CVD. 
Variable Model 1 Model 2 
Non-CVD CVD Non-CVD CVD 
Parameter 
estimate 
(SE) 
p-
value 
Parameter 
estimate 
(SE) 
p-
value 
Parameter 
estimate 
(SE) 
p-
value 
Parameter 
estimate 
(SE) 
p-
value 
Risk factor 
of primary 
interest 
AHI 
ODI 
        
 
0.006 
(0.004) 
 
0.084 
 
0.011 
(0.004) 
 
0.009 
    
    0.005 
(0.004) 
0.188 0.007 
(0.003) 
0.030 
Age 
0.007 
(0.008) 
0.347 
0.017 
(0.009) 
0.049 
0.008 
(0.008) 
0.340 
0.019 
(0.009) 
0.037 
Sex 
(reference 
is male) 
Female 
 
-0.185 
(0.175) 
 
0.294 
 
0.014 
(0.211) 
 
0.948 
 
-0.195 
(0.177) 
 
0.274 
 
-0.059 
(0.213) 
 
0.783 
BMI 
-0.014 
(0.016) 
0.388 
0.009 
(0.014) 
0.513 
-0.009 
(0.017) 
0.575 
0.011 
(0.014) 
0.454 
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5.4 Kidney function and level of kidney injury 
There was no difference in eGFR between groups (Figure 5.7A, Table 5.12). The mean 
eGFR values for severe OSA patients were within the normal range 91.6 ±16.7 ml/min/1.73m2). 
Mildly decreased eGFR was observed for control (88.6 ± 12.2 ml/min/1.73m2), mild OSA (87.6 ± 
14.0 ml/min/1.73m2) and moderate OSA (83.6 ± 30.5 ml/min/1.73m2). 
The NGAL level did not differ between groups (Figure 5.7C, Table 5.12). There was no 
significant difference in mean ACR level between groups (Figure 5.7B, Table 5.12). However, the 
more severe sleep apnea, the higher ACR mean values. ACR means for control, mild and moderate 
OSA were within the range of category of normal to mildly increase albuminuria (1.0 ± 2.1; 1.2 ± 
2.1; 1.9 ± 4.9 mg/mmol, respectively), severe OSA patients had moderately increased albuminuria 
(6.7 ± 7.0 mg/mmol). 
 
 
Table 5.12 Kidney function and kidney injury in study patients. 
 Control Obstructive sleep apnea  
Mild Moderate Severe p-value 
eGFR  88.6 ± 12.2 87.6 ± 14.0 83.6 ± 30.5 91.6 ±16.7 0.476 
ACR 1.0 ± 2.1 1.2 ± 2.1 1.9 ± 4.9 4.5 ± 13.8 0.211 
NGAL 6.0 ± 6.2 -  7.5 ± 9.8 6.7 ± 7.0 0.865 
 
 
 There was statistically significant difference in urinary MMP-2 activity (adjusted for 
creatinine – indicator of hydration status) in OSA patients stratified by level of albuminuria 
(normal to mildly increased vs moderately to severely increased) (p = 0.042, Figure 5.7D). 
Simple linear regression showed statistically significant associations with urinary MMP-2 
activity-to-creatinine for ACR (p = 0.020, Figure 5.8), serum MMP-2 (p = 0.016), and 
hypertension (p = 0.022) – see Table 5.13. The association between ACR and urinary MMP-2-to-
creatinine persisted after adjustment for eGFR, serum MMP-2, age, sex, BMI, hypertension and 
type 2 diabetes (Table 5.14).
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Figure 5.7 Level of kidney function and kidney injury in study subjects. 
Level of kidney function measured by eGFR (estimated glomerular filtration rate) (A); level of 
kidney injury measured by NGAL (neutrophil gelatinase associated lipocalin) (B); level of 
glomerular injury measured by ACR (albumin-to-creatinine ratio) (C); urinary MMP-2 per 
creatinine in in OSA patients in regards to level of glomerular damage (D). 
*p < 0.05 vs another group; mean, error bars: 95% confidence interval. 
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Figure 5.8 Linear regression of urinary MMP-2/creatinine and ACR in study subjects.
   52 
 
Table 5.13 Crude linear regression analysis of ln urinary MMP-2-to-creatinine on potentially 
important covariates. 
Variable r Parameter 
estimate (SE) 
p-value 
ACR 0.223 0.301 (0.127) 0.020 
eGFR 0.147 -0.012 (0.009) 0.174 
MMP-2 in serum 0.219 0.380 (0.156) 0.016 
Age 0.176 0.022 (0.011) 0.055 
Sex (reference is male) 
Female 
 
0.005 
 
-0.014 (0.288) 
 
0.961 
BMI 0.001 0.000 (0.018) 0.995 
Type 2 diabetes (reference is No) 
Yes 
 
0.046 
 
0.200 (0.401) 
 
0.619 
Systemic hypertension  
Yes 
0.209 0.660 (0.284) 0.022 
AHI 0.103 0.005 (0.005) 0.261 
 
Table 5.14 Results from multiple linear regression analysis with urinary MMP-2-to-creatinine as 
the outcome. 
Variable Parameter estimate (SE) p-value 
ACR 0.406 (0.173) 0.022 
eGFR -0.012 (0.011) 0.256 
MMP-2 in serum 0.270 (0.216) 0.217 
Age -0.002 (0.015) 0.888 
Sex (reference is male) 
Female 
 
-0.436 (0.333) 
 
0.195 
BMI -0.013 (0.027) 0.621 
Type 2 diabetes (reference is No) 
Yes 
 
-0.618 (0.471) 
 
0.194 
Systemic hypertension (reference is No) 
Yes 
0.268 (0.358) 0.457 
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 DISCUSSION 
Recurrent episodes of complete and/or partial obstruction of upper airways in OSA frequently 
result in a repetitive transient decrease in arterial oxygen saturation and may in turn lead to 
oxidative stress [10]. Intermittent hypoxia and arousals initiate the adverse physiological and 
biochemical sequelae which result in numerous adverse consequences including cardiovascular 
disease [9,94]. It has been  shown that a 10-unit average increase in AHI was associated with a 
17% greater risk of CVD in OSA [7]. Therefore, finding a simple non-invasive biomarker of 
severity of OSA and hypoxic burden is crucial, as it can help identify those OSA patients who may 
be at risk of adverse consequences related to OSA severity [8]. Different molecules (including 
vascular proteins, adhesion molecules, inflammatory markers, catecholamines and oxidative stress 
markers) have been explored as potentially useful prognostic biomarkers, however, the result are 
inconsistent [24]. There are plausible biological mechanisms, including oxidative stress and 
inflammation, linking MMPs and OSA (see Figure 3.1). 
 
The main results of my thesis are as followed: 
− Patients with OSA and without OSA significantly differ in regards to serum MMP-2 
activity. 
− Serum MMP-2 activity was significantly associated with OSA severity/level of 
hypoxemia in OSA, even after adjustment for sex, BMI and CVD. 
− Serum MMP-9 activity was associated with white blood cells count, independently of 
AHI/ODI, age, sex, BMI and CVD. 
− Urinary MMP-2 activity was associated with glomerular proteinuria (independently of 
hypertension and diabetes). 
− There were no differences in MMP-2 and MMP-9 activities between patients with and 
without CVD, however, when stratified by CVD, the association between serum 
MMP-2 and AHI/ODI remain significant only for patients with CVD. 
 
6.1 MMP-2 in serum 
The previous evidence linking MMP-2 and OSA severity is scarce. A systematic review 
[15] revealed only three papers concerning circulating MMP-2 in adults with OSA [70,74,76]. 
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Among them, one study [70] reported an increased MMP-2 plasma level in OSA patients, another  
[76] showed no association between OSA and serum levels of MMP-2, and the last one [74] 
reported that MMP-2 level in serum was lower in patients with severe OSA compared to subjects 
with less severe sleep apnea. 
The results of our study demonstrate higher activity of serum MMP-2 in OSA than in 
controls (Figure 5.1). The results can be explained by the fact that MMP-2 is synthesized as an 
inactive zymogen, and can be activated by ROS [45], which are produced during CIH [10,95]. The 
results are also in accordance with a study on human endothelial cell culture which showed that 
hypoxia significantly enhanced MMP-2 activity [57]. 
Moreover, it was shown in a rat model that acute ischemia/reperfusion injury leads to 
marked activation of MMP-2, which was positively associated with duration of ischemia [44]. The 
severity of OSA is associated with greater number of apnea/hypopnea events and thus oxidative 
stress increases along with OSA severity (there was a strong correlation between AHI and ODI in 
our cohort; r = 0.952, β(SE) = 1.072 (0.028), p<0.001). Therefore, the positive associations 
between serum MMP-2 and AHI as well as MMP-2 and particularly ODI, which were found in 
this study, are not surprising (Table 5.6). The inconsistency with the previous findings can result 
from insufficient statistical power because of low sample sizes (ranging between 50-79). Also, 
using RDI for quantification of OSA severity, as was done previously, does not properly reflect 
the hypoxemic insult in OSA patients, and underestimation of desaturations could be even greater 
than in case of using AHI. It is possible that patients with less severe OSA (RDI<30) experienced 
higher desaturations (higher oxidative stress) than severe OSA patients (RDI>30), and it could be 
an explanation for results observed by Bonanno et al. [74] who reported lower serum MMP-2 level 
in patients with severe OSA (RDI>30) compared to subjects with less severe OSA (RDI<30). 
However, due to limited data in study of Bonanno et al. we cannot assess if this reasoning could 
be confirmed. 
MMP-2 has been previously shown to be associated with CVD, and interestingly, when 
results were stratified by CVD status, the association between serum MMP-2 activity and 
AHI/ODI remained significant only for patients with CVD (Table 5.11). However, the interaction 
between OSA severity and CVD cannot be fully assessed, as the study might not have enough 
statistical power.  
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OSA exposes cardiovascular system to various noxious stimuli (oxidative stress, 
inflammation, endothelial dysfunction, autonomic dysregulation, negative intrathoracic pressure) 
[96]. All of these can mediate the development or progression of CVD. While in our study CVD 
was a composite measure, in future larger studies MMP-2 should be thoroughly investigated in the 
subgroups of patients with different CVDs. 
Increased MMP levels has been shown in clinical and experimental models of systemic 
hypertension [97]. Apart from ROS and inflammatory cytokines, MMP-2 can be activated by 
angiotensinogen II [98], which is frequently elevated in OSA patients, especially those with 
hypertension [99]. 
Yamazaki et al. has shown that serum MMP-2 was significantly associated with level of 
plasma brain natriuretic peptide (BNP) in patients with heart failure [100]. BNP is a cardiac 
hormone, which is a predictor of risk of death in patients with heart failure or cardiac dysfunction 
[101]. 
It has been reported that plasma MMP-2 levels increased after myocardial infarctions [102] 
and after coronary artery bypass graft surgery [103]. Thus, MMP-2 may also be associated with 
coronary artery disease in OSA. 
The mechanical stress on heart in OSA (related to negative intrathoracic pressure) and 
hypoxemia can lead to ventricular hypertrophy, atrial fibrosis and remodelling [104], which  
predispose to atrial fibrillation. The upregulation of MMP-2 has been  observed in atrial tissue of 
patients with atrial fibrillation [105].   
 Changes in circulating MMP-2 have also been reported in stroke patients. The study of 
Lucivero et al. [106] suggested that MMP-2 can be related to better outcome (plasma MMP-2 level 
was higher in patients with stable or recovering symptoms in comparison to those who underwent 
neurological worsening, and MMP-2 negatively correlated with stroke severity). Therefore, MMP-
2 might be a prognostic marker for stroke outcomes in OSA. 
 Furthermore, although the difference in prevalence of diabetes between different groups 
was not statistically significant in our study (yet increasing along with OSA severity – see Table 
5.3), it is important to emphasize the clinical significance of diabetes on CVD development in 
OSA. OSA and diabetes often coexist, as they share some risk factors such as obesity. [107]. There 
is a higher risk of atherosclerosis and CVD mortality in OSA patients with diabetes, compared to 
those without diabetes [108]. Even though it is difficult to define causality in these relationships, 
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it is possible that MMP-2 is a mediator. It has been shown in animal and cell studies that MMP-2 
may contribute to development of diabetic complications (not only cardiopathy [109], but also 
retinopathy [110] and nephropathy [111]). Thus, MMP-2 action should be explored in larger 
studies on OSA patients with diabetes. 
 
6.2 MMP-9 in serum 
The majority of previous studies on MMPs in OSA have focused on MMP-9, and in our 
systematic review [15] five out of eight studies examining the relationship between circulating 
MMP-9 and OSA in adult patients showed that MMP-9 level was elevated in patients with OSA 
in comparison to patients without OSA or those with less severe OSA [56,70–73].  
Fang et al. in their review and meta-analysis on MMP-9 in OSA [112] confirmed that the 
peripheral level of MMP-9 was increased in OSA patients, and the increase was relevant to OSA 
severity. Different inclusion and exclusion criteria resulted in a higher number of papers included 
by Fang et al. in their review - seven out of 12 papers showed increased MMP-9 levels in adult 
OSA patients [112]. In contrast, four reported no difference in MMP-9 level between patients with 
more severe OSA in comparison with controls or those with less severe OSA [74–76,78]; and one 
article showed that serum MMP-9 level was significantly lower in severe OSA than in controls 
[113]. 
However, the positive results were not confirmed in this study. There was no significant 
difference in MMP-9 activity between OSA patients and controls (Figure 5.1), and the difference 
in MMP-9 activity between groups with different OSA severity did not suggest linear association 
with oxidative stress related to OSA (Figure 5.2). 
Interestingly, only three [74,75,78] (out of 5) studies showing negative results were 
included in the meta-analysis of Fang et al. [112]. Among the excluded papers, the study of Volná 
et al. [76] is worth mentioning. They did not report any significant difference in blood MMP-9 
concentration in regards to OSA severity, but the pattern observed for different OSA severity was 
similar to the one observed in our cohort. Specifically, there was a noticeable drop in MMP-9 
levels in the moderate OSA group. Both age and BMI were similar between studies. Unfortunately, 
more detailed comparison is impossible, due to limited data in the study of Volná et al. [76]. 
It is worth emphasizing that most of previous studies were methodologically flawed in that 
they measured MMP concentration rather than activity. MMPs are produced as inactive zymogens, 
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thus, in respect to MMP biology, enzyme activity is a far more informative measurement. Among 
previous studies there are only two that measured MMP activity, and they showed conflicting 
results. Tazaki et al. [72] showed that serum MMP-9 activity was higher in patients with 
moderate/severe OSA than those with mild OSA or controls, whereas Nizam et al. [113] showed 
that serum MMP-9 activity was significantly lower in patients with severe OSA compared to 
controls. Thus, MMP-9 activity cannot be suggested as a marker of severity based on this study. 
Our results showed that serum MMP-9 activity was associated with WBC count, 
independently of AHI/ODI, age, sex, BMI and CVD (Table 5.8). These results are in accordance 
with study of Snitker et al. carried out on apparently healthy population suggesting that the main 
source of circulating MMP-9 are WBC [114].  
Causation cannot be inferred from the results of any observational study, however, the 
putative mechanism leading to changes in circulating MMP-9 activity seems to be inflammation 
(measured as WBC count [115]), rather than oxidative stress itself. MMP-9, unlike MMP-2, is 
highly inducible by inflammatory processes [34]. The associations between OSA severity and total 
WBC and neutrophil counts have been previously shown [116]. Along this line of thinking, WBC 
count (or inflammation it represents) could be on a causal pathway linking OSA severity with 
MMP-9 level. However, multicollinearity between AHI/ODI and WBC was not found in our 
analysis (VIF values for AHI and WBC were 1.15 and 1.36, respectively).  
Kaditis et al. also showed that plasma MMP-9 was significantly associated with CRP 
(indicator of inflammation) and BMI, but not with AHI [78]. The positive correlation between 
CRP and serum MMP-9 level was also shown by Ye et al. [73] (however, MMP-9 was associated 
with AHI). Except for the studies where patients with systemic or respiratory inflammation were 
excluded [56,72], the authors did not address the potential confounding of inflammation in their 
analysis on MMP-9 in OSA patients. 
It is likely that inflammation via MMP-9 could be a link between OSA and CVD. 
Neutrophils – the most numerous type of WBC - are a measure of chronic inflammatory state, and 
even within normal range, they were shown to be associated linearly with risk of developing 
myocardial infarction, ischemic stroke, heart failure and peripheral artery disease [117], all of 
which are seen in OSA patients. Oxidative stress related to OSA can modulate WBC action, 
leading to release of MMP-9 [71]. MMP-9 in turn can contribute to development and progression 
of atherosclerosis [118] – a condition underlying many cardiovascular disorders. 
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6.3 MMPs in urine 
Nocturnal hypoxemia has been previously shown to be associated with kidney injury [20] 
and loss of kidney function [19] in OSA patients. The detrimental effect of OSA on the kidneys 
may be either due to direct effect of intrarenal hypoxia, or as an indirect result of oxidative stress, 
inflammation and activation of renin-angiotensin-aldosterone system (RAAS). RAAS facilitate 
systemic hypertension and glomerular hyperfiltration, which can lead to progression of glomerular 
damage  [119].  
There was no evidence of tubular injury (measured as NGAL) in our cohort, which is in 
accordance with the study carried out by Maski et al. [120]. The eGFR values of our study subjects 
did not indicate hyperfiltration, however, we have had only one-time measurement of eGFR, which 
could have been assessed during the intermediate state – before or after a supraphysiological 
increase in GFR. 
It needs to be kept in mind that eGFR can be within normal range even in the presence of 
considerable loss of nephron mass [121]. In order to assess the level of glomerular damage, ACR 
was calculated. In our cohort, in more severe OSA, a higher ACR was observed; which is in 
accordance with the results showing that OSA is associated with increased urinary albumin 
excretion [122]. In this study, urinary MMP-2-to-creatinine was significantly associated with 
ACR, even after adjustment for eGFR, serum MMP-2, age, sex, BMI, and presence of 
hypertension and diabetes (Table 5.14).  
Given that urinalysis is an inexpensive, safe and common test, urinary measurements could 
be an easily accessible source of information useful for OSA management. To the best of our 
knowledge, this is the first study investigating MMPs in urine samples of OSA patients. The results 
have shed some light on urinary MMPs activity, showing that urinary MMP-2 level in OSA was 
associated with glomerular injury (measured as ACR), independently of hypertension and diabetes. 
As causality cannot be established directly in cross-sectional studies, it is uncertain if 
urinary MMP-2 activity is elevated as a result of glomerular damage, or if it is MMP-2 that causes 
the damage. The latter idea is consistent with some previous studies showing that MMP action can 
modulate renal microvascular permeability (through cleavage of type IV collagen - the main 
component of glomerular basement membrane), and mediate glomerulosclerosis and 
tubulointerstitial fibrosis [123]. 
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We found a trend (p = 0.084) towards higher urinary MMP-9 activity in OSA patients 
compared to controls (Figure 5.1), and the difference was more prominent and significant between 
severe OSA and controls (Figure 5.2). However, regression analysis did not confirm any 
significant associations with neither AHI nor any measurements of kidney function (eGFR, ACR, 
NGAL) (data not shown). 
Alteration in urinary MMP levels has been previously shown in acute and chronic renal 
injury [123–125], and the results of our study provide a link between urinary MMP-2 and 
nephropathy (namely glomerular damage) in OSA. 
OSA often occurs in the presence of other comorbidities, and both OSA and its comorbid 
conditions often share common risk factors (such as age or obesity) and may have overlapping 
pathophysiology (oxidative stress and inflammation among others) [107]. It has been suggested 
that OSA and chronic kidney disease are potentially related in a bidirectional fashion [126]. Thus, 
similarly to analysis in serum, it is very difficult to discern the individual factor contributing to 
changes in urinary MMP levels in OSA. 
 
6.4 Study limitations 
Although this study has provided important insight into association between MMP activity 
and OSA, there are several limitations that should be acknowledged. First, the effect size was lower 
than expected and, in several cases, the achieved power was not sufficient. Second, patient self-
reporting of cardiovascular comorbidities may be listed as the possible limitation, however, it was 
verified by chart review, which includes all the medical history and work-up from referring 
physicians. 
Further, the selection of various control groups should be discussed. The study subjects 
were chosen from those referred to the Sleep Disorders Center and may not be representative of 
general population. The choice of different control groups could lead to different associations 
between MMPs and OSA. In our case, the associations may be an underestimate. The reason is 
that because the patients were referred to the clinic, they may be experiencing another sleep 
condition and would be more likely to have an elevated MMP due to that underlying condition or 
any other source of inflammation/oxidative stress than those in the general population, or the 
reason for being referred to the clinic may be related to outcome (Berkson bias). An alternative 
control population could have been healthy controls from general population. This would allow 
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for a comparison of MMP in OSA patients to a group with no underlying conditions and allow a 
true comparison of background MMP. However, this control group would probably differ from 
those who were referred to the clinic. Thus, their selection would be challenging in order to not 
introduce any additional bias. The differences in age, body mass/BMI and prevalence of CVD seen 
between our cases and controls represent the situation commonly observed in the clinical setting 
which makes the results more applicable. Given all discussed, in future studies it would be useful 
to consider multiple control groups (“healthy” control in addition to ours). 
Also, even though we controlled for many plausible confounders, the results of any 
observational studies need to be interpreted keeping in mind the possibility of residual 
confounding. 
 
6.5 Strengths of the study 
This study differs from others on this subject in several aspects: it has a larger sample size 
(N = 150 including 124 OSA patients), performance of in-lab PSG in each subject, classification 
of OSA according to American Academy of Sleep Medicine criteria, and controlling for potential 
confounders.  
The previous studies did not control for WBC count, which could have led to unreliable 
results as leukocytes are the main source of circulatory MMP-9 [34,114]. Also, MMP-9 is highly 
inducible by inflammatory processes, which can mediate increases in WBC counts and MMP-9 
release. However, the majority of other studies neither controlled for WBC count, nor for 
inflammation; except from few in which patients with systemic or respiratory inflammation were 
excluded [56,72] or those where CRP was an additional independent variable in the analysis 
[73,78].  
Moreover, we measured MMPs activity, unlike other studies measuring MMPs 
concentration. MMPs are produced as inactive zymogens, thus, in respect to MMP biology, 
enzyme activity is a far more informative measurement.  
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 CONCLUSIONS 
Consistent with our hypothesis, serum MMP-2 activity was associated with OSA 
severity/level of hypoxemia in OSA. However, such association did not exist for MMP-9. Serum 
MMP-9 was associated with WBC count (which reflects inflammation). 
There were no differences in MMP activities between OSA patients with CVD and without 
CVD. However, in stratified analysis, the association between serum MMP-2 and AHI remained 
significant only for patients with CVD. It may imply a potential link between OSA, MMP-2 and 
CVD. It suggests MMP-2 should be investigated thoroughly in this subgroup as a potential marker 
of CVD, although this should also be interpreted with caution, as interaction could not be fully 
assessed. 
Urinary MMPs were not shown to be associated with OSA severity. Urinary MMP-2 in 
OSA was associated with ACR, independently of hypertension and diabetes. It suggests it could 
be an indicator of glomerular damage in OSA. However, ACR is a commonly used, approved and 
recommended measurement in this regard.  
An ideal biomarker of OSA should be disease-specific and disease-sensitive (for screening 
purposes), treatment-responsive (for treatment monitoring), and involved in a causal pathway (for 
prediction OSA comorbidities) [8]. The plausible biological mechanisms (oxidative stress and 
inflammation) linking MMPs with OSA and its comorbidities justify the interest and hope given 
to MMPs by researchers in sleep medicine. 
Due to the multifactorial pathophysiology of OSA and its comorbidities, it seems prudent 
to consider the combination of biomarkers in future research. The associations for serum MMPs 
found in our study are promising. MMP-2 (associated with AHI/ODI) and MMP-9 (associated 
with WBC counts) could address different causes underlying OSA, namely oxidative stress and 
inflammation. 
Future studies should be prospective in their design, and include a larger sample size in 
order to increase statistical power. In addition, subgroup analysis of patients with different CVDs 
should be carried out. Moreover, the effect of CPAP treatment on MMP activities is yet to be 
determined. 
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Appendix A. Search details 
1) Embase – Ovid, Embase Classic+Embase (1947 to 2018 December 05) 
1. matrix metalloproteinase/ or metalloproteinase/ 
 
2. metalloproteinase*.mp. 
 
3. mmp*.mp. 
 
4. metallopeptidase*.mp. 
 
5. 1 or 2 or 3 or 4 
 
6. sleep disordered breathing/ 
 
7. (sleep adj2 (apnea or apnoea or breathing)).mp. 
 
8. "hypopnea OR hypopnoea".mp. 
 
9. (disorder* adj2 breathing).mp. 
 
10. 6 or 7 or 8 or 9 
 
11. 5 and 10 
 
 
2) Medline via Ovid - Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-
Indexed Citations, Daily and Versions(R) (1946 to 2018 December 05) 
1. metalloendopeptidases/ or exp gelatinases/ or exp matrix metalloproteinases/ 
 
2. metalloproteinase*.mp. 
 
3. mmp*.mp. 
 
4. metallopeptidase*.mp. 
 
5. 1 or 2 or 3 or 4 
 
6. sleep apnea syndromes/ or exp sleep apnea, obstructive/ 
 
7. (sleep adj2 (apnea or apnoea or breathing)).mp. 
 
8. "hypopnea OR hypopnoea".mp. 
 
9. (disorder* adj2 breathing).mp. 
 
10. 6 or 7 or 8 or 9 
 
11. 5 and 10   
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Appendix B. Quality assessment 
Author, reference number Selection 
(★★★★) 
Comparability  
(★★) 
Outcome/Exposure 
(★★★★) 
Bonanno et al. (2016) [74] ★★   ★★★ 
Dantas et al. (2012) [79] ★★★ ★ ★★★★ 
Hopps et al. (2016) [70] ★★  ★★★ 
Kaditis et al. (2010) [78] ★★★ ★★ ★★★ 
Maeder et al. (2015) [75] ★ ★  ★★★★ 
Tamaki et al. (2009) [71] ★★ ★★ ★★★ 
Tazaki et al. (2004) [72] ★★ ★ ★★★ 
Volná et al. (2011) [76]  ★  ★★★ 
Wang et al. (2018) [56]  ★  
Ye et al. (2007) [73]  ★★★ ★★ ★★★ 
 
For assessing the quality of studies, the modified Newcastle-Ottawa Scale (NOS) was used: Wells 
GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale 
(NOS) for assessing the quality if nonrandomized studies in meta-analyses. Available from: URL: 
http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (cited Jan 25, 2019). 
